Abstract
Synopsis
Ciprofloxacin is a broad spectrum fluoroquinolone antibacterial agent. Since its introduction in the 1980s, most Gram-negative bacteria have remained highly susceptible to this agent in vitro; Gram-positive bacteria are generally susceptible or moderately susceptible. Ciprofloxacin attains therapeutic concentrations in most tissues and body fluids. The results of clinical trials with Ciprofloxacin have confirmed its clinical efficacy and low potential for adverse effects.
Ciprofloxacin is effective in the treatment of a wide variety of infections, particularly those caused by Gram-negative pathogens. These include complicated urinary tract infections, sexually transmitted diseases (gonorrhoea and chancroid), skin and bone infections, gastrointestinal infections caused by multiresistant organisms, lower respiratory tract infections (including those in patients with cystic fibrosis), febrile neutropenia (combined with an agent which possesses good activity against Gram-positive bacteria), intra-abdominal infections (combined with an antianaerobic agent) and malignant external Otitis. Ciprofloxacin should not be considered a first-line empirical therapy for respiratory tract infections if penicillin-susceptible Streptococcus pneumoniae is the primary pathogen; however, it is an appropriate treatment option in patients with mixed infections (where S. pneumoniae may or may not be present) or in patients with predisposing factors for Gram-negative infections.
Clinically important drug interactions involving Ciprofloxacin are well documented and avoidable with conscientious prescribing. Recommended dosage adjustments in patients with impaired renal function vary between countries; major adjustments are not required until the estimated Creatinine clearance is <30 ml/min/1.73m2 (or when the serum Creatinine level is≥2 mg/dl).
Ciprofloxacin is one of the few broad spectrum antibacterials available in both intravenous and oral formulations. In this respect, it offers the potential for cost savings with sequential intravenous and oral therapy in appropriately selected patients and may allow early discharge from hospital in some instances.
In conclusion, Ciprofloxacin has retained its excellent activity against most Gram-negative bacteria, and fulfilled its potential as an important antibacterial drug in the treatment of a wide range of infections. Rational prescribing will help to ensure the continued clinical usefulness of this valuable antimicrobial drug.
Overview of Antibacterial Activity
Ciprofloxacin is very active in vitro against most Gram-negative bacteria including Enterobacteriaceae (especially enteropathogens such as Escherichia coli, Salmonella spp. and Shigella spp.), Neisseria spp., Moraxella catarrhalis and Haemophilus spp., with MIC90 (minimum concentration of Ciprofloxacin inhibiting 90% of strains) values much lower than the susceptibility cut-off value (1 mg/L). Reports from a number of European centres of increasing resistance to Ciprofloxacin among Enterobacteriaceae are of concern.
Ciprofloxacin remains active in vitro against Pseudomonas aeruginosa. Progressively decreasing susceptibility among P. aeruginosa has been reported in Europe and North and South America, predominantly in hospital or nursing home settings in patients with identifiable risk factors. Epidemiological studies suggest that this decreased susceptibility is the result of selection and horizontal transmission of fluoroquinolone-resistant clones. Decreased susceptibility of Campylobacter spp. to Ciprofloxacin has been reported in Spain, Finland, The Netherlands and Greece.
The majority of methicillin-susceptible strains of Staphylococcus aureus are susceptible to Ciprofloxacin while most methicillin-resistant S. aureus (MRSA) strains are resistant (MIC90 ≥4 mg/L). The drug has been shown to select for ciprofloxacin-resistant coagulase-negative staphylococci when it is used as prophylaxis in neutropenic patients and as treatment in patients with chronic ambulatory peritoneal dialysis (CAPD) peritonitis.
Streptococcus pneumoniae, including penicillin-resistant strains, are generally susceptible or moderately susceptible (MIC90 1 or 2 mg/L). Like most fluoroquinolones, Ciprofloxacin has little activity against anaerobic bacteria.
Pharmacokinetic Properties
Ciprofloxacin has an approximate bioavailability of 70% after oral administration. Maximum plasma concentrations (Cmax) between 0.8 and 3.9 mg/L are achieved 1 to 2 hours after oral administration of single 250 to 750mg doses. The drug has a large apparent volume of distribution (2.1 to 5 L/kg after oral or intravenous administration) and is concentrated in many body tissues and fluids, including bile and kidney, liver, gallbladder, prostate and lung tissue.
Ciprofloxacin is largely excreted unmetabolised in the urine and faeces, although small amounts of metabolites have been detected. Transintestinal elimination appears to be the predominant route of gastrointestinal elimination, but bile excretion also occurs. The elimination half-life (t½β) is approximately 3 to 5 hours.
As a result of age-related decrease in renal function, renal clearance of Ciprofloxacin is decreased, and thus Cmax, t½β and AUC values are increased in elderly versus younger patients. Similar variations in these parameters for Ciprofloxacin have also been noted in patients with renal impairment.
Therapeutic Efficacy
With its broad spectrum of antibacterial activity and ability to achieve therapeutic concentrations in most body fluids and tissues, Ciprofloxacin has proved useful in the treatment of a wide variety of infections.
Clinical and bacteriological cure rates for uncomplicated urinary tract infections were >90% with 3- to 7-day Ciprofloxacin regimens (500 mg/day; >90% of patients were female), and were slightly lower with single-dose regimens. A3-day course of low-dose Ciprofloxacin (100mg twice daily) was as effective as cotrimoxazole (trimethoprim-sulfamethoxazole) [3- and 7-day regimens], nitrofurantoin (7 days) and Ofloxacin (3 days) in this indication. Cure rates ranged from 76 to 96% in complicated urinary tract infections, and Ciprofloxacin was as effective as cotrimoxazole, ceftazidime, aminoglycosides and other fluoroquinolones.
Ciprofloxacin showed efficacy similar to that of ceftriaxone, ceftazidime and fleroxacin and greater than that of imipenem-cilastatin in patients with pneumonia (mostly nosocomial). In patients with acute exacerbation of chronic bronchitis, rates of cure/improvement were generally >90% and were similar to those achieved with rufloxacin, cotrimoxazole, amoxicillin (with and without clavulanic acid), Ceftibuten, Cefixime, cefuroxime axetil and Cefaclor. Although the use of fluoroquinolones in the treatment of lower respiratory tract infections in which S. pneumoniae is a suspected pathogen is an issue of concern, a recent review showed that the clinical and bacteriological efficacy of Ciprofloxacin are similar to that of traditional agents in these infections, including those caused by S. pneumoniae.
Ciprofloxacin was as effective as cefuroxime axetil and amoxicillin-clavulanic acid, respectively, in the treatment of acute and chronic sinusitis. Clinical and bacteriological cure rates with Ciprofloxacin in patients with chronic Otitis media ranged from 58 to 70% and were higher than with amoxicillin-clavulanic acid in one study. High cure rates were observed in the treatment of malignant Otitis externa (>95%); compared with historical controls, Ciprofloxacin markedly shortened the hospital stay in this infection.
Single-dose, 3- or 5-day Ciprofloxacin regimens produced cure or marked improvement in approximately 90% of patients with travellers’ and non-traveller’ diarrhoea and shigellosis (including infections caused by multiresistant strains). Ciprofloxacin was also shown to be effective in controlling institutional outbreaks of salmonellosis, but microbiological relapse rates varied between studies; prolonged faecal excretion of salmonellae is a concern. Cure rates of 100% were reported in patients with typhoid fever, including those with up to 40% multiresistant strains, in most studies. 14-day regimens may be more effective than 7-day regimens in patients with symptoms for ≥10 days duration. Ciprofloxacin produced cure rates of 100% in patients with cholera and reduced symptom duration.
Ciprofloxacin treatment of skin/skin structure infections was as effective as cefotaxime, ceftazidime and other fluoroquinolones in moderate to severe infections. Increased resistance to MRSA would appear to limit its usefulness as first-line empirical therapy in these infections, most notably in institutions where MRSA predominate. Ciprofloxacin is effective in the treatment of osteomyelitis, where it has been used as sequential therapy to facilitate early discharge from hospital.
Ciprofloxacin monotherapy is probably not appropriate in patients with febrile neutropenia. The ideal regimen in this infection remains to be defined, but ciprofloxacin-containing combination regimens appear to be at least as effective as standard regimens. Ciprofloxacin has demonstrated usefulness as prophylaxis in patients with neutropenia; however, this practice potentially limits its future usefulness as empirical treatment and increases the potential for development of resistance.
In a limited number of comparative trials, Ciprofloxacin, in combination with an antianaerobic agent, has demonstrated efficacy similar to that of amoxicillin/clavulanic acid plus metronidazole and that of imipenem-cilastatin in intra-abdominal infection. In patients undergoing CAPD, Ciprofloxacin (25 to 50 mg/L per dialysate bag) appeared to be more effective than oral Ciprofloxacin in the treatment of peritonitis. Its clinical activity against Gram-positive pathogens in this setting has not been encouraging and further clarification is needed. Ciprofloxacin monotherapy showed similar efficacy to standard combination regimens in the treatment of pelvic inflammatory disease, endometritis and gallbladder infections; anaerobic pathogens accounted for the majority of treatment failures in ciprofloxacin-treated patients with gynaecological infections, indicating that the addition of an antianaerobic agent may be appropriate in these infections.
Data, mostly from noncomparative trials, indicate that sequential intravenous and oral Ciprofloxacin is effective in the treatment of bacteraemia/sepsis in non-neutropenic patients. Oral and intravenous Ciprofloxacin has been used successfully as preoperative prophylaxis in patients undergoing urological, biliary tract, vascular or colorectal surgery.
Clinical and bacteriological cure rates of 99.5% have been reported in gonococcal infections following single-dose Ciprofloxacin (100 to 2000mg; 69% received 250mg) administration. It is as effective as standard agents and other fluoroquinolones. Clinical cure rates of 92 to 100% have been reported in patients with chancroid following single-dose Ciprofloxacin (500mg). Because of its moderate activity against Chlamydia trachomatis, Ciprofloxacin is not recommended for treatment of non-gonococcal Urethritis.
Although not currently approved for use in patients <18 years old, Ciprofloxacin produced clinical improvement in >90% of respiratory tract infections and demonstrated efficacy similar to that of combination intravenous regimens in paediatric patients with cystic fibrosis. Additionally, nearly 100% of children with life-threatening multiresistant typhoid fever were cured with Ciprofloxacin.
Pharmacoeconomic Considerations
Oral Ciprofloxacin treatment is effective in some infections which would other-wise require parenteral therapy and can be used as sequential therapy after parenteral antibacterial agents. Accordingly, a number of investigators have shown cost savings with oral Ciprofloxacin in hospitalised patients, based on the assumption that the more expensive parenteral regimen would have continued had oral Ciprofloxacin not been available. Treatment with oral Ciprofloxacin also allowed early discharge of some patients, thereby substantially reducing overall treatment costs.
In two prospective randomised trials conducted in the US, sequential Ciprofloxacin therapy reduced antibacterial drug costs by approximately 45% compared with parenteral therapy and reduced hospitalisation costs by 20%. Retrospective cost analyses applied to recent prospective clinical trials showed that intravenous Ciprofloxacin was more cost effective than ceftazidime in patients with nosocomial pneumonia and 40% less costly than initial treatment with imipenem-cilastatin in patients hospitalised with severe pneumonia.
Used appropriately, Ciprofloxacin can be less costly and/or more cost effective than traditional parenteral regimens in selected clinical settings. More well designed studies would be helpful in further defining the most cost-efficient use of this antimicrobial agent.
Tolerability
Evidence from clinical trials and postmarketing surveillance studies confirms the good tolerability of oral Ciprofloxacin. Overall, ciprofloxacin-related adverse events were reported in approximately 9% of patients, and led to treatment withdrawal in 1.5% of patients. Gastrointestinal adverse events, mainly nausea, diarrhoea, vomiting, dyspepsia, anorexia or abdominal pain, were reported in ≈5% of Ciprofloxacin recipients. CNS (mostly dizziness, headache, restlessness or tremors) and dermatological (mostly rash or pruritus) adverse events were the next most frequently reported events (≈2 and ≈1% of patients, respectively). Most events were mild to moderate in severity; serious adverse events occurred in <1 % of patients. Ciprofloxacin is rarely associated with phototoxicity. Careful examination of adverse event data has revealed no evidence of temafloxacin-like adverse reactions.
With the exception of local reactions at the site of administration (1 % of 5010 patients from clinical trials), the tolerability profile of intravenous or sequential intravenous and oral Ciprofloxacin appears similar to that of oral Ciprofloxacin. Ciprofloxacin appears to be well tolerated in elderly (>65 years) and younger patients. Although the use of Ciprofloxacin is restricted in patients <18 years old because of concerns over cartilage damage, accumulated data in >1500 paediatric patients treated with Ciprofloxacin suggest a similar tolerability profile in children/adolescents and adults.
Ciprofloxacin is rarely associated with clinically relevant changes in laboratory parameters. Metabolic or nutritional disorders occur in ≈4% of patients; alterations are mostly elevations in serum glutamic oxaloacetic transaminase and/or glutamic pyruvic transaminase levels (incidence of ≈1.5% each). Changes in renal function are rare, with elevated serum Creatinine and blood urea nitrogen levels occurring in 0.25% of patients.
Drug Interactions
Concurrent administration of Ciprofloxacin and theophylline can increase plasma concentrations of the latter, which may increase the potential for theophylline-related adverse events. Multivalent cation-containing preparations (e.g. aluminium- or magnesium-based antacids, iron-, calcium- or zinc-containing preparations, enterai nutrition products, didanosine and sucralfate) can substantially reduce the bioavailability of Ciprofloxacin.
Dosage and Administration
Oral and intravenous Ciprofloxacin are normally administered in twice-daily regimens. Recommended dosages of oral Ciprofloxacin are 500 to 1500mg daily, depending on the site and severity of infection. Intravenous dosages usually range from 400 to 800mg daily and are infused over at least 60 minutes to minimise venous irritation; higher dosages (up to 1200 mg/day) have been used in patients with serious life-threatening infections. Duration of treatment depends on infection severity but is usually 7 to 14 days, or at least 2 days after disappearance of signs and symptoms of infection. Shortened regimens have been used in some infections, e.g. 3 to 7 days’ treatment in infectious diarrhoea, 3 days’ treatment (100 or 250mg twice daily) in acute uncomplicated cystitis and single-dose treatment in patients with acute uncomplicated gonococcal Urethritis. Bone and joint infections generally require longer treatment durations (e.g. 4 to 6 weeks or longer).
The international dosing guidelines in renally impaired patients recommend maximum oral and intravenous Ciprofloxacin dosages of 1000 and 800 mg/day, respectively, in patients with a Creatinine clearance between 31 and 60 ml/min/1.73m (or a serum Creatinine level of between 1.4 and 1.9 mg/dl), and 500 and 400 mg/day, respectively, in patients with a Creatinine clearance ≤30 ml/min/1.73m2 (or a serum Creatinine level of ≥2 mg/dl). Ciprofloxacin is not currently approved for use in pregnant or lactating women, or in children and adolescents <18 years of age.
Plasma theophylline concentrations should be monitored and dosage adjustments made as appropriate with concurrent administration of Ciprofloxacin. If concomitant administration of multivalent cation-containing preparations cannot be avoided, Ciprofloxacin should be administered at least 2 hours before or 6 hours after administration of these products.
Article PDF
Similar content being viewed by others
References
Campoli-Richards DM, Monk JP, Price A, et al. Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1988 Apr; 35: 373–447
Ferrero L, Cameron B, Crouzet J. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother 1995 Jul; 39: 1554–8
Hoshino K, Kitamura A, Morrissey I, et al. Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition. Antimicrob Agents Chemother 1994 Nov; 38: 2623–7
Ferrero L, Cameron B, Manse B, et al. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol Microbiol 1994; 13: 641–53
Hooper DC. Quinolone mode of action. Drugs 1995; 49 Suppl. 2: 10–5
Wakebe H, Mitsuhashi S. Comparative in vitro activitites of a new quinolone, OPC-17116, possessing potent activity against gram-positive bacteria. Antimicrob Agents Chemother 1992 Oct; 36: 2185–91
Gootz TD, Brighty KE, Anderson MR, et al. In vitro activity of CP-99, 219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial. Diagn Microbiol Infect Dis 1994 Aug; 19: 235–43
Iwasaki H, Miyazaki S, Tsuji A. In vitro and in vivo antibacterial activities of Q-35, a novel fluoroquinolone. Chemotherapy (Basel) 1995 Mar–Apr; 41: 100–12
McCarter YS, Mazens-Sullivan MF, Bartlett RC. The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents. Chemotherapy (Basel) 1992 Sep-Oct; 38: 308–18
Chin N-X, Neu HC. In-vitro activity of WIN 57273 compared to the activity of other fluoroquinolones and two β-lactam antibiotics. J Antimicrob Chemother 1991 Jun; 27: 781–91
García-Rodríguez JA, García Sanchez JE, García Garcia MI, et al. In-vitro activity of four new fluoroquinolones. J Antimicrob Chemother 1994 Jul; 34: 53–64
Eliopoulos GM, Klimm K, Grayson ML. In vitro activity of Sparfloxacin (AT-4140, CI-978, PD 131501), a new quinolone antimicrobial agent. Diagn Microbiol Infect Dis 1990 Jul–Aug; 13: 345–8
Eliopoulos GM, Wennersten CB, Cole G, et al. In vitro activity of A-86719.1, a novel 2-pyridone antimicrobial agent. Antimicrob Agents Chemother 1995 Apr; 39: 850–3
Bauernfeind A. Comparative in-vitro activities of the new quinolone, Bay y 3118, and Ciprofloxacin, Sparfloxacin, tosufloxacin, CI-960 and CI-990. J Antimicrob Chemother 1993 Apr; 31: 505–22
Sader HS, Jones RN, Allen SD, et al. In vitro comparison activity of OPC-17116, a new fluoroquinolone, against more than 5,000 recent clinical isolates from five medical centers. J Chemother 1993 Oct; 5: 283–8
Fuchs PC, Barry AL, Pfaller MA. Multicenter evaluation of the in vitro activities of three new quinolones, Sparfloxacin, CI-960, and PD 131,628, compared with the activity of Ciprofloxacin against 5,252 clinical bacterial isolates. Antimicrob Agents Chemother 1991 Apr; 35: 764–6
Marco F, Jones RN, Hoban DJ, et al. In-vitro activity of OPC-17116 against more than 6000 consecutive clinical isolates: a multicentre international study. J Antimicrob Chemother 1994 Mar; 33: 647–54
Murray PR, Cantrell HF, Lankford RB, et al. Multicenter evaluation of the in vitro activity of piperacillin-tazobactam compared with eleven selected β-lactam antibiotics and Ciprofloxacin against more than 42,000 aerobic Gram-positive and Gram-negative bacteria. Diagn Microbiol Infect Dis 1994 Jun; 19: 111–20
Biedenbach DJ, Jones RN. In vitro evaluation of DV-7751a, a new fluoroquinolone with an enhanced spectrum of activity against Gram-positive aerobic organisms and anaerobes. Antimicrob Agents Chemother 1995 Jul; 39: 1636–43
Fuchs PC, Barry AL, Pfaller MA. Antibacterial activity of PD 131628 and proposed disc diffusion susceptibility test criteria. J Antimicrob Chemother 1994 Jun; 33: 1147–54
Inderlied CB, Lancero MG, Bermudez LM, et al. In vitro activity of lomefloxacin as compared with Ciprofloxacin. Diagn Microbiol Infect Dis 1989 May–Jun; 12 Suppl.: 17S–20S
Dholakia N, Rolston KVI, Ho DH, et al. Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones. Antimicrob Agents Chemother 1994 Apr; 38: 848–52
Jones RN. In vitro evaluation of E-4695, a new fluoro-naphthyridine. Eur J Clin Microbiol Infect Dis 1992 Feb; 11: 188–94
Barrett MS, Jones RN, Erwin ME. In vitro activity of E-4868, a new trifluoroquinolone, compared to six similar compounds. Eur J Clin Microbiol Infect Dis 1993 Feb; 12: 134–41
Jolley A, Andrews JM, Brenwald N, et al. The in-vitro activity of a new highly active quinolone, DU-6859a. J Antimicrob Chemother 1993 Nov; 32: 757–63
Child J, Andrews J, Boswell F. The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. J Antimicrob Chemother 1995 Jun; 35: 869–76
Flamm RK, Vojtko C, Chu DTW, et al. In vitro evaluation of ABT-719, a novel DNA gyrase inhibitor. Antimicrob Agents Chemother 1995 Apr; 39: 964–70
Gooding BB, Jones RN. In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrob Agents Chemother 1993 Feb; 37: 349–53
Tanaka M, Otsuki M, Une T, et al. In-vitro and in-vivo activity of DR-3355, an optically actove isomer of Ofloxacin. J Antimicrob Chemother 1990 Nov; 26: 659–66
Rolston KVI, Nguyen HT, Ho DH. In vitro activity of Ro 23-9424, a dual-action antibacterial agent, against bacterial isolates from cancer patients compared with those of other agents. Antimicrob Agents Chemother 1992 Apr; 36: 879–82
Digranes A, Hardardottir H, Bottolfsen KL. Temafloxacin: in vitro comparison with five other antibacterial agents. Chemotherapy (Basel) 1991 Mar–Apr; 37: 98–105
Cantón E, Pemán J, Jiminez MT. In vitro activity of Sparfloxacin compared with those of five other quinolones. Antimicrob Agents Chemother 1992 Mar; 36: 558–65
Guinea J, Gargallo-Viola D, Robert M, et al. E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. Antimicrob Agents Chemother 1995 Feb; 39: 413–21
Paganoni R, Herzog C, Braunsteiner A, et al. Fleroxacin: in-vitro activity worldwide against 20,807 clinical isolates and comparison to Ciprofloxacin and norfloxacin. J Antimicrob Chemother 1988 Oct; 22 Suppl. D: 3–17
Jones RN, Erwin ME. In vitro activity of CP-74667 compared with four other fluoroquinolones. Diagn Microbiol Infect Dis 1992 Aug; 15: 531–6
Cooper MA, Andrews JM, Wise R. In-vitro activity of PD 131628, a new quinolone antimicrobial agent. J Antimicrob Chemother 1992 May; 29: 519–27
Powell M, Seetulsingh P, Williams JD. In-vitro susceptibility of Haemophilus influenzae to meropenem compared with imipenem, five other β-lactams, chloramphenicol and Ciprofloxacin. J Antimicrob Chemother 1989 Sep; 24 Suppl. A: 175–81
Prosser BLT, Beskid G. Multicenter in vitro comparative study of fluoroquinolones against 25,129 Gram-positive and Gram-negative clinical isolates. Diagn Microbiol Infect Dis 1995 Jan; 21: 33–45
Brunnengraber R, Friedberg KD. The effects of the 4-quinolones Ciprofloxacin and Ofloxacin on the humoral immune response of healthy and immune suppressed mice [abstract]. Naun Schmied Arch Pharmacol 1991; 343 Suppl.: 85
Speciale A, Caccamo F, Cocuzza C, et al. Susceptibility of 1,787 nosocomial pathogens to Ciprofloxacin and other antibiotics. Curr Ther Res 1990 Jan; 47: 226–38
Waites K, Rand K, Jenkins S, et al. Multicenter in vitro comparative study of fluoroquinolones after four years of widespread clinical use. Diagn Microbiol Infect Dis 1994 Mar; 18: 181–9
Smith BR. National cooperative study of Ciprofloxacin susceptibility in the United States. Curr Ther Res 1990 Jun; 47: 962–70
Nani E, Lavitola A, Lembo M, et al. Evaluation of Ciprofloxacin’s activity against recent clinical isolates. J Chemother 1989 Aug; 1: 223–5
Amyes SGB, Baird DR, Crook DW, et al. A multicentre study of the in-vitro activity of cefotaxime, cefuroxime, ceftazidime, Ofloxacin and Ciprofloxacin against blood and urinary pathogens. J Antimicrob Chemother 1994 Nov; 34: 639–48
Fass RJ. In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci. Antimicrob Agents Chemother 1991 Mar; 35: 553–9
Bongaerts GPA, Hoogkamp-Korstanje JAA. In vitro activities of BAY Y3118, Ciprofloxacin, Ofloxacin, and fleroxacin against Gram-positive and Gram-negative pathogens from respiratory tract and soft tissue infections. Antimicrob Agents Chemother 1993 Sep; 37: 2017–9
Korten V, Tomayko JF, Murray BE, et al. Comparative in vitro activity of DU-6859a, a new fluoroquinolone agent, against gram-positive cocci. Antimicrob Agents Chemother 1994 Mar; 38: 611–5
Goto S, Miyazaki S, Kaneko Y. The in-vitro activity of RP 59500 against Gram-positive cocci. J Antimicrob Chemother 1992 Jul; 30 Suppl. A: 25–8
Freeman C, Robinson A, Cooper B, et al. In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci. Diagn Microbiol Infect Dis 1995 Jan; 21: 47–50
Toma E, Barriault D. Antimicrobial activity of fusidic acid and disk diffusion susceptibility testing criteria for gram-positive cocci. J Clin Microbiol 1995 Jul; 33: 1712–5
Barry AL, Fuchs PC. Antistaphylococcal activity of the fluoroquinolones CI-960, PD 131628, Sparfloxacin, Ofloxacin and Ciprofloxacin. Eur J Clin Microbiol Infect Dis 1991 Mar; 10: 168–71
Hardy DJ. Activity of temafloxacin and other fluoroquinolones against typical and atypical community-acquired respiratory tract pathogens. Am J Med 1991 Dec 30; 91: 12S–4S
Maple PA, Hamilton-Miller JM, Brumfitt W. Differing activities of quinolones against ciprofloxacin-susceptible and ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1991 Feb; 35: 345–50
Smith KR, Cobbs CG. In vitro activity of Sparfloxacin and three other fluoroquinolones against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis. Eur J Clin Microbiol Infect Dis 1992 Jan; 11: 55–8
Lehtonen L, Huovinen P. Susceptibility of respiratory tract pathogens in Finland to Cefixime and nine other antimicrobial agents. Scand J Infect Dis 1993; 25 (3): 373–8
Neal TJ, O’Donoghue MAT, Ridgway EJ, et al. In-vitro activity of ten antimicrobial agents against penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 1992 Jul; 30: 39–46
Nelson CT, Mason Jr EO, Kaplan SL. Activity of oral antibiotics in middle ear and sinus infections caused by penicillin-resistant Streptococcus pneumoniae: implications for treatment. Pediatr Infect Dis J 1994 Jul; 13: 585–9
King A, Bethune L, Phillips I. The in-vitro activity of tosufloxacin, a new fluorinated quinolone, compared with that of Ciprofloxacin and temafloxacin. J Antimicrob Chemother 1991 Nov; 28: 719–25
Spangler SK, Jacobs MR, Appelbaum PC. Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, Sparfloxacin, temafloxacin, Win 57273, Ofloxacin, and Ciprofloxacin. Antimicrob Agents Chemother 1992 Apr; 36: 856–9
Eliopoulos GM, Klimm K, Eliopoulos CT. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of Gram-positive bacteria. Antimicrob Agents Chemother 1993 Feb; 37: 366–70
Raymond NJ, Bremner DA. The in-vitro activity of biapenem against 964 clinical isolates of aerobic bacteria. J Antimicrob Chemother 1995 May; 35: 681–6
Venezia RA, Yocum DM. The in vitro activity of oral Ciprofloxacin and beta-lactam antimicrobials against bacteria from the respiratory tract. Curr Ther Res 1991 Aug; 50: 282–7
Edwards JR. Meropenem: a microbiological review. J Antimicrob Chemother 1995; 36 Suppl. A: 1–17
Malmborg A-S, Ahlén S. In vitro activity of Sparfloxacin compared with Ciprofloxacin and Ofloxacin against respiratory tract pathogens. Chemotherapy (Basel) 1993 Jan–Feb; 39: 32–5
Thornsberry C. Susceptibility of clinical bacterial isolates to Ciprofloxacin in the United States. Infection 1994; 22 Suppl. 2: S80–9
Jones RN, Hoban DJ. North American (United States and Canada) comparative susceptibility of two fluoroquinolones: Ofloxacin and Ciprofloxacin. A 53-medical-center sample of spectra of activity. North American Ofloxacin Study Group. Diagn Microbiol Infect Dis 1994 Jan; 18: 49–56
Jones RN, Kehrberg EN, Erwin ME. Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States. I. Study on the threat of emerging resistances: real or perceived?. Diagn Microbiol Infect Dis 1994 Aug; 19: 203–15
Fernandes CJ, Ackerman VP. In vitro studies of Ciprofloxacin and survey of resistance patterns in current isolates. Diagn Microbiol Infect Dis 1990 Mar–Apr; 13: 79–91
Beskid G, Prosser BLT. A multicenter study on the comparative in vitro activity of fleroxacin and three other quinolones: an interim report from 27 centers. Am J Med 1993 Mar 22; 94 Suppl. 3A: 2S–8S
Rao PS, Rajashekar V, Varghese GK, et al. Emergence of multi-drug-resistant Salmonella typhi in rural southern India. Am J Trop Med Hyg 1993 Jan; 48: 108–11
Campos LC, Falavinados Reis EM, Cavalcante de Albuquerque Ribeiro Dias J. In vitro susceptibility of Salmonella to Ciprofloxacin and pefloxacin compared with three other antibiotics. Chemotherapy (Basel) 1990 Jan; 36: 29–32
Reina J, Gomez J, Serra A, et al. Analysis of the antibiotic resistance detected in 2043 strains of Salmonella enterica subsp. enterica isolated in stool cultures of Spanish patients with acute diarrhoea (1986–1991). J Antimicrob Chemother 1993 Nov; 32: 765–9
AlóS JI, Gómez-Garcés JL, Cogollos R, et al. Susceptibilities of ampicillin-resistant strains of Salmonella other than S. typhi to 10 antimicrobial agents. Antimicrob Agents Chemother 1992 Aug; 36: 1794–6
John JJF, Atkins LT, Maple PAH, et al. Activities of newer fluoroquinolones against Shigella sonnei. Antimicrob Agents Chemother 1992 Oct; 36: 2346–8
López-Brea M, Alarcón T, Baquero M, et al. Antimicrobial susceptibility of Shigella strains to new fluoroquinolones. Rev Esp Quimioter 1990 Mar; 3: 83–5
Vila J, Gascon J, Abdalla S, et al. Antimicrobial resistance of Shigella isolates causing traveler’s diarrhea. Antimicrob Agents Chemother 1994 Nov; 38: 2668–70
Kambal AMM, Chowdhury MNH, Al-Eissa YA, et al. Susceptibility of Shigella species to various antimicrobial agents in Saudi Arabia. Med Sci Res 1994 Dec 1–31; 22: 867–9
Martinez-Martinez L, Suárez AI, Carranza R, et al. Resistance to Ciprofloxacin in gram negative bacilli. Epidemiologic aspects [in Spanish]. Enfermed Infecc Microbiol Clin 1993 Nov; 11: 474–8
Gómez J, Hernández Cardona JL, Sanmiguel T, et al. Ciprofloxacin use and resistance in a general hospital. Prospective study 1988–1991 [in Spanish]. Rev Esp Quimioter 1992 Dec; 5: 317–9
Mirelis B, Miro E, Navarro F, et al. Increased resistance to quinolone in Catalonia, Spain. Diagn Microbiol Infect Dis 1993 Feb; 16: 137–9
Peña C, Albareda JM, Pallares R, et al. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob Agents Chemother 1995 Feb; 39: 520–4
Aguiar JM, Chacon J, Canton R, et al. The emergence of highly fluoroquinolone-resistant Escherichia coli in community-acquired urinary tract infections [letter]. J Antimicrob Chemother 1992; 28: 349–50
Pérez-Trallero E, Urbieta M, Jimenez D, et al. Ten-year survey of quinolone resistance in Escherichia coli causing urinary tract infections. Eur J Clin Microbiol Infect Dis 1993; 12: 349–51
Grünberg RN, Felmingham D. The susceptibility of urinary tract pathogens to Ciprofloxacin during the period 1987–1992 [abstract no. 441]. The 18th International Congress of Chemotherapy; 1993 Jun 27–Jul 2; Stockholm, 196.
Weber P, Plaisance J-J, Mancy C. Lack of increase in resistance to quinolones in general practice isolates of Escherichia coli [letter]. J Antimicrob Chemother 1994; 34: 187–8
Cometta A, Calandra T, Bille J, et al. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia [letter]. N Engl J Med 1994 Apr 28; 330: 1240–1
Kern WV, Andriof E, Oethinger M, et al. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 1994 Apr; 38: 681–7
Carratalá J, Fernández-Sevila A, Tubau F, et al. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 1995; 20: 557–60
Coronado VG, Edwards JR, Culver DH, et al. Ciprofloxacin resistance among nosocomial Pseudomonas aeruginosa and staphylococcus aureus in the United States. Infect Control Hosp Epidemiol 1995 Feb; 16: 71–5
Dalhoff A. Quinolone resistance in Pseudomonas aeruginosa and Staphylococcus aureus. Development during therapy and clinical significance. Infection 1994; 22 Suppl. 2: S111–121
Kresken M, Hafner D, Mittermayer H, et al. Prevalence of fluoroquinolone resistance in Europe. Infection 1994; 22 Suppl. 2: 90–8
Goldstein FW, Acar JF. Epidemiology of quinolone resistance: Europe and North and South America. Drugs 1995; 49 Suppl. 2: 36–42
Dalhoff A. Clinical perspectives of quinolone resistance in Pseudomonas aeruginosa. In: Homma JY, Tanimoto H, Holder IA, et al., editors. Pseudomonas aeruginosa in Human Diseases, v. 44. Basel: Basel, Karger, 1991: 221–39
Chandrasekar PH, Sluchak JA. In-vitro susceptibility of cefoperazone-susceptible and resistant Gram-negative rods to cefoperazone plus sulbactam, other beta-lactams, aminogly-cosides and quinolone. Infection 1991 Jan–Feb; 19: 49–53
Diez EM. In vitro activity of aztreonam, cefotaxime, ceftazidime and imipenem combined with Ciprofloxacin against Gram-negative bacilli and compared with amikacin combinations against Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis 1991 Feb; 10: 90–2
Bustamante CI, Wharton RC, Wade JC. In vitro activity of Ciprofloxacin in combination with ceftazidime, aztreonam, and azlocillin against multiresistant isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1990 Sep; 34: 1814–5
Pankuch GA, Jacobs MR, Appelbaum PC. Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, Ciprofloxacin, and Ofloxacin. Antimicrob Agents Chemother 1994 Feb; 38: 369–70
Lesco-Bornet M, Pierre J, Sarkis-Karam D, et al. Susceptibility of Xanthomonas maltophilia to six quinolones and study of outer membrane proteins in resistant mutants selected in vitro. Antimicrob Agents Chemother 1992 Mar; 36: 669–71
Reina J, Borrell N, Serra A. Emergence of resistance to eryth-romycin and fluoroquinolones in thermotolerant Campylo-bacter strains isolated from feces 1987–1991. Eur J Clin Microbiol Infect Dis 1992 Dec; 11: 1163–6
Sánchez R, Fernńdez-Baca V, Díaz MD, et al. Evolution of susceptibilities of Campylobacter spp. to quinolones and macrolides. Antimicrob Agents Chemother 1994 Sep; 38: 1879–82
Rautelin H, Renkonen O-V, Kosunen TU. Azithromycin resistance in Campylobacter jejuni and Campylobacter coli. Eur J Clin Microbiol Infect Dis 1993 Nov; 12: 864–5
Endtz HP, Ruijs GJ, van Klingeren B, et al. Quinolone resistance in campylobacter isolated from man and poultry following the introduction of fluoroquinolones in veterinary medicine. J Antimicrob Chemother 1991; 27: 199–208
Chatzipanagiotou S, Papavasiliou E, Malamou-Lada E. Isolation of Campylobacter jejuni strains resistant to nalidixic acid and fluoroquinolones from children with diarrhea in Athens, Greece. Eur J Clin Microbiol Infect Dis 1993 Jul; 12: 566–8
Le NP, Bryskier A, Le ND, et al. Activity of four fluoroquinolones against 346 strains of enteric pathogens. J Antimicrob Chemother 1993 Mar; 31: 447–50
Howard BMA, Smith JT. Post antibiotic effects of Ciprofloxacin [abstract]. J Pharm Pharmacol 1991 Dec; 43 Suppl.: 12P
Knapp JS, Ohye R, Neal SW, et al. Emerging in vitro resistance to quinolones in penicillinase-producing Neisseria gonorrhoeae strains in Hawaii. Antimicrob Agents Chemother 1994 Sep; 38: 2200–3
Knapp JS, Washington JA, Doyle LJ, et al. Persistence of Neisseria gonorrhoeae strains with decreased susceptibilities to ciprofloxacin and ofloxacin in Cleveland, Ohio, from 1992 through 1993. Antimicrob Agents Chemother 1994 Sep; 38: 2194–6
Fluoroquinolone resistance in Neisseria gonorrhoeae-Colorado adn Washington, 1995. MMWR Morb Mortal Wkly Rep 1995; 44: 761-4
Whittington WL, Xia M, Wolfe T, et al. Sustained transmission of a unique strain of Neisseria gonorrhoeae with high-level fluoroquinolone resistance [abstract no. LB-21]. In: 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco. 1995: 11
From the Centers for Disease Control and Prevention. Decreased susceptibility of Neisseria gonorrhoeae to fluoroquinolones—Ohio and Hawaii, 1992–1994. JAMA 1994 Jun 8; 271: 1733–4
Jacobs MR. Activity of quinolones against mycobacteria. Drugs 1995; 49 Suppl. 2: 67–75
Van der Willigen AH, van Rijsoord-Vos T, Wagenvoort JHT, et al. Antimicrobial susceptibility and serotyping of Chlamydia trachomatis strains isolated before and after treatment with Ciprofloxacin and doxycycline. Eur J Clin Microbiol Infect Dis 1992 Jun; 11: 561–3
Wise R, Andrews JM. In vitro activities of two glycylcyclines. Antimicrob Agents Chemother 1994 May; 38: 1096–102
Wise R, Andrews JM, Brenwald N. The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone. J Antimicrob Chemother 1993 Apr; 31: 497–504
Schaberg DR, Dillon WI, Terpenning MS, et al. Increasing resistance of enterococci to Ciprofloxacin. Antimicrob Agents Chemother 1992 Nov; 36: 2533–5
Naber KG, Witte W, Bauernfeind A, et al. Clinical significance and spread of fluoroquinolone resistant uropathogens in hospitalised urological patients. Infection 1994; 22 Suppl. 2: S122–7
Appelbaum PC. Quinolone activity against anaerobes: microbiological aspects. Drugs 1995 Suppl. 2: 76–80
Power EGM, Muñoz Bellido JL, Phillips I. Detection of Ciprofloxacin resistance in Gram-negative bacteria due to alterations in gyrA. J Antimicrob Chemother 1992 Jan; 29: 9–17
Bryan LE, Bedard J. Impermeability to quinolones in Gram-positive and Gram-negative bacteria. Eur J Clin Microbiol 1991; 10: 232–9
Piddock LJV. Mechanisms of resistance to fluoroquinolones: state-of-the-art. Drugs 1995; 49 Suppl. 2: 29–35
Watanabe M, Kotera Y, Yosue K, et al. In vitro emergence of quinolone-resistant mutants of Escherichia coli, Enterobacter cloacae, and Serratia marcescens. Antimicrob Agents Chemother 1990 Jan; 34: 173–5
Wiedemann B, Heisig P. Mechanisms of quinolone resistance. Infection 1994; 22 Suppl. 2: S73–9
Michéa-Hamzehpour M, Kahr A, Pechère J-C. In vitro stepwise selection of resistance to quinolones, β-lactams and amikacin in nosocomial gram-negative bacilli. Infection 1994; 22 Suppl. 2: S105–10
Ball P. Emergent resistance to Ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus aureus: clinical significance and therapeutic approaches. J Antimicrob Chemother 1990 Dec; 26 Suppl. F: 165–79
Muder RR, Brennen C, Goetz AM, et al. Association with prior fluoroquinolone therapy of widespread Ciprofloxacin resistance among gram-negative isolates in a Veterans Affairs medical center. Antimicrob Agents Chemother 1991 Feb; 35: 256–8
Grüneberg RN. Changes in urinary pathogens and their antibiotic sensitivities, 1971–1992. J Antimicrob Chemother 1994 May; 33 Suppl. A: 1–8
Yee YC, Muder RR, Hsieh MH, et al. Molecular epidemiology of endemic ciprofloxacin-susceptible and ciprofloxacin-resistant Enterobacteriaceae. Infect Control Hosp Epidemiol 1992 Dec; 13: 706–10
Sanders CC, Sanders Jr WE, Goering RV, et al. Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes. Antimicrob Agents Chemother 1984; 26: 797–801
Sanders CC, Watanakunakorn C. Emergence of resistance to β-lactams, aminoglycosides and quinolones during combination therapy due to Serratia marcescens. J Infect Dis 1986; 153: 617–9
Diver JM, Schollaardt T, Rabin HR, et al. Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing Ciprofloxacin therapy. Antimicrob Agents Chemother 1991 Aug; 35: 1538–46
Denis A, Moreau NJ. Mechanisms of quinolone resistance in clinical isolates: accumulation of Sparfloxacin and of fluoroquinolones of various hydrophobicity, and analysis of membrane composition. J Antimicrob Chemother 1993 Sep; 32: 379–92
Aubert G, Pozzetto B, Dorche G. Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy. J Antimicrob Chemother 1992 Mar; 29: 307–12
Rådberg G, Nilsson LE, Svensson S. Development of quinolone-imipenem cross resistance in Pseudomonas aeruginosa during exposure to Ciprofloxacin. Antimicrob Agents Chemother 1990 Nov; 34: 2142–7
Fung-Tomc J, Kolek B, Bonner DP. Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1993 Jun; 37: 1289–96
Fass RJ, Barnishan J, Ayers LW. Emergence of bacterial resistance to imipenem and Ciprofloxacin in a university hospital. J Antimicrob Chemother 1995; 36: 343–53
Lee YL, Cesario T, Lee R, et al. Colonization by Staphylococcus species resistant to methicillin or quinolone on hands of medical personnel in a skilled-nursing facility. Am J Infect Control 1994 Dec; 22: 346–51
Daum TE, Schaberg DR, Terpenning MS, et al. Increasing resistance of Staphylococcus aureus to Ciprofloxacin. Antimicrob Agents Chemother 1990 Sep; 34: 1862–3
Harnett N, Brown S, Krishnan C. Emergence of quinolone resistance among clinical-isolates of methicillin-resistant Staphylococcus aureus in Ontario, Canada. Antimicrob Agents Chemother 1991 Sep; 35: 1911–3
Sader HS, Pignatari AC, Hollis RJ, et al. Oxacillin- and quinolone-resistant Staphylococcus aureus in Sao Paulo, Brazil: a multicenter molecular epidemiology study. Infect Control Hosp Epidemiol 1993 May; 14: 260–4
Hillery SJ, Reiss-Levy EA. Increasing Ciprofloxacin resistance in MRSA [letter]. Med J Aust 1993 Jun 21; 158: 861, 863
Voss A, Milatovic D, Wallrauch-Schwarz C, et al. Methicillin-resistant Staphylococcus aureus in Europe. Eur J Clin Microbiol Infect Dis 1994; 13: 50–5
Budnick LD, Schaefler S. Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in New York health care facilities, 1988. The New York MRSA Study Group. Am J Public Health 1990 Jul; 80: 810–3
Smith SM, Eng RHK, Bais P, et al. Epidemiology of Ciprofloxacin resistance among patients with methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1990 Oct; 26: 567–72
Raviglione MC, Boyle JF, Mariuz P, et al. Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital. Antimicrob Agents Chemother 1990 Nov; 34: 2050–4
Brumfitt W, Hamilton-Miller J. Methicillin-resistant Staphylococcus aureus. N Engl J Med 1989; 320: 1188–96
Barry AL, Pfaller MA, Fuchs PC. Spontaneously occurring staphylococcal mutants resistant to clinically achievable concentrations of Ciprofloxacin and temafloxacin. Eur J Clin Microbiol Infect Dis 1992 Mar; 11: 243–6
Doss SA, Tillotson GS, Barg NL, et al. In-vitro and in-vivo selection of Staphylococcus aureus mutants resistant to Ciprofloxacin. J Antimicrob Chemother 1995 Jan; 35: 95–102
Kotilainen P, Nikoskelainen J, Huovinen P. Emergence of ciprofloxacin-resistant coagulase-negative staphylococcal skin flora in immunocompromised patients receiving Ciprofloxacin. J Infect Dis 1990 Jan; 161: 41–4
Brumfitt W, Hamilton-Miller JMT. Incomplete cross-resistance between Ciprofloxacin and Sparfloxacin in staphylococci, with a note on selection pressure due to clinical use of Ciprofloxacin. J Antimicrob Chemother 1993 Apr; 31: 610–2
Dryden MS, Talsania H, McCann M, et al. The epidemiology of Ciprofloxacin resistance in coagulase-negative staphylococci in CAPD patients. Epidemiol Inf 1992 Aug; 109: 97–112
Trucksis M, Hooper DC, Wolfson JS. Emerging resistance to fluoroquinolones in staphylococci: an alert. Ann Intern Med 1991; 114: 424–6
Cruciani M, Bassetti D. The fluoroquinolones as treatment for infections caused by Gram-positive bacteria. J Antimicrob Chemother 1994 Mar; 33: 403–17
Dryden MS, Ludlam HA, Phillips I. 4-Quinolone resistant staphylococci. J Antimicrob Chemother 1990 Sep; 26: 448–9
Wilcox MH, Finch RG. Ciprofloxacin and CAPD peritonitis [letter]. J Antimicrob Chemother 1990 Sep; 26: 447–8
Oppenheim BA, Hartley JW, Lee W, et al. Outbreak of coagulase negative staphylococcus highly resistant to Ciprofloxacin in a leukaemia unit. BMJ 1989 Jul 29; 299: 294–7
Hedin G, Hambraeus A. Multiply antibiotic-resistant Staphylococcus epidermidis in patients, staff and environment—a one-week survey in a bone marrow transplant unit. J Hosp Infect 1991; 17: 95–106
Wiseman LR, Balfour JA. Ciprofloxacin: a review of its pharmacological profile and therapeutic use in the elderly. Drugs Aging 1994 Feb; 4: 145–73
Vance-Bryan K, Guay DRP, Rotschafer JC. Clinical pharmacokinetics of Ciprofloxacin. Clin Pharmacokinet 1990 Dec; 19: 434–61
Catchpole C, Andrews JM, Woodcock J, et al. The comparative pharmacokinetics and tissue penetration of single-dose Ciprofloxacin 400 mg iv and 750 mg po. J Antimicrob Chemother 1994 Jan; 33: 103–10
Lettieri JT, Rogge MC, Kaiser L, et al. Pharmacokinetic profiles of Ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother 1992 May; 36: 993–6
Shah A, Blum R, Millikin S, et al. Pharmacokinetics of 400 mg IV Ciprofloxacin in normal and renally impaired subjects [abstract]. In: 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1994: 19
Shah A, Lettieri J, Nix D, et al. Pharmacokinetics of high-dose intravenous Ciprofloxacin in young and elderly and in male and female subjects. Antimicrob Agents Chemother 1995 Apr; 39: 1003–6
Cohn SM, Cohn KA, Rafferty MJ, et al. Enteric absorption of Ciprofloxacin during the immediate postoperative period. J Antimicrob Chemother 1995; 36: 717–21
Gould I, Neilly IJ, Dawson AA, et al. Oral absorption of Ciprofloxacin in leukaemic patients with chemotherapy induced neutropenia and sepsis [abstract]. In: 7th European Congress of Clinical Microbiology and Infectious Diseases. 1995: 245
Marangos MN, Skoutelis AT, Nightingale CH, et al. Absorption of Ciprofloxacin in patients with diabetic gastroparesis. Antimicrob Agents Chemother 1995; 39: 2161–3
Patel KB, Belliveau PP, Nightingale CH, et al. Absorption of Ciprofloxacin n febrile and afebrile patients. Int J Antimicrob Agents 1995; 6: 119–22
Bergan T. Extravascular penetration of Ciprofloxacin. A review. Diagn Microbiol Infect Dis 1990 Mar–Apr; 13: 103–14
Fabre D, Bressolle F, Gomeni R, et al. Steady-state pharmacokinetics of Ciprofloxacin in plasma from patients with nosocomial pneumonia: penetration of the bronchial mucosa. Antimicrob Agents Chemother 1991 Dec; 35: 2521–5
Reid TMS, Gould IM, Golder D, et al. Brief report: respiratory tract penetration of Ciprofloxacin. Am J Med 1989 Nov 30; 87 Suppl. 5A: 60S–1S
Rohwedder R, Bergan T, Caruso E, et al. Penetration of Ciprofloxacin and metabolites into human lung, and bronchial and pleural tissue after 250 and 500 mg oral Ciprofloxacin. Chemotherapy (Basel) 1991 Jul–Aug; 37: 229–38
Imai K, Suzuki K, Yamanaka H, et al. Concentrations of new quinolone agents in serum and prostate tissue [in Japanese]. Hinyokika Kiyo 1994 May; 40: 401–6
Morita M, Nakagawa H. Ciprofloxacin concentration in human prostatic tissue following 3-days administration [in Japanese]. Hinyokika Kiyo 1991 May; 37: 563–6
Naber KG, Sörgel F, Kinzig M, et al. Penetration of Ciprofloxacin into prostatic fluid, ejaculate and seminal fluid in volunteers after an oral dose of 750 mg. J Urol 1993 Nov; 150: 1718–21
Berger SA, Yavetz H, Paz G, et al. Concentration of Ofloxacin and Ciprofloxacin in human semen following a single oral dose. J Urol 1990 Sep; 144: 683–4
Giamarellou H, Kanellas D, Kavouklis E. Comparative pharmacokinetics of Ciprofloxacin, Ofloxacin and Pefloxacin in human aqueous humour. Eur J Clin Microbiol Infect Dis 1993 Apr; 12: 293–7
Sweeney G, Fern AI, Lindsay G, et al. Penetration of Ciprofloxacin into the aqueous humour of the uninflamed human eye after oral administration. J Antimicrob Chemother 1990 Jul; 26: 99–105
Keren G, Alhalel A, Bartov E, et al. The intravitreal penetration of orally administered Ciprofloxacin in humans. Invest Ophthalmol Vis Sci 1991 Jul; 32: 2388–92
El BFZ, Trousdale MD, Gauderman WJ, et al. Intravitreal penetration of oral Ciprofloxacin in humans. Ophthalmology, 1992 Apr; 99: 483–6
Lesk MR, Ammann H, Marcil G, et al. The penetration of oral Ciprofloxacin into the aqueous humor, vitreous, and subretinal fluid of humans. Am J Ophthalmol 1993 May 15; 115: 623–8
Sorgel F, Naber KG, Jaehde U, et al. Brief report: gastrointestinal secretion of Ciprofloxacin. Evaluation of the charcoal model for investigations in healthy volunteers. Am J Med 1989 Nov 30; 87 Suppl. 5A: 62S–5S
Rohwedder R, Bergan T, Thorsteinsson SB, et al. Transintestinal elimination of Ciprofloxacin. Chemotherapy (Basel) 1990 Mar–Apr; 36: 77–84
Stass H, Bianchi W, Kuhlmann J, et al. Pharmacokinetics of Ciprofloxacin in AIDS-patients suffering from opportunistic bacterial infections. Pharm Res 1994 11 (Suppl.): 447
Peltola H, Väärälä M, Renkonen O-V. Pharmacokinetics of single-dose oral Ciprofloxacin in infants and small children. Antimicrob Agents Chemother 1992 May; 36: 1086–90
Rubio TT, Miles MV, Church DA, et al. Pharmacokinetic studies of Ciprofloxacin in children with cystic fibrosis [abstract]. Pediatr Res 1994 Apr; 35(Part 2): 195A
Schaefer HG, Stass H, Wedgwood J, et al. Pharmacokinetics of Ciprofloxacin in pediatric cystic fibrosis patients. Antimicrob Agents Chemother 1996; 40: 29–34
Beam Jr. TR, Gilbert DN, Kunin CM. General guidelines for the clinical evaluation of anti-infective drug products. Clin Infect Dis 1992; 15 Suppl. 1: S5–S32
Schentag JJ, Nix DE, Adelman MH. Mathematical examination of dual individualization principles (I): relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. DICP 1991 Oct; 25: 1050–7
Peloquin CA, Cumbo TJ, Nix DE, et al. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. Arch Intern Med 1989 Oct; 149: 2269–73
Righter J. Ciprofloxacin treatment of Staphylococcus aureus infections. J Antimicrob Chemother 1987; 20: 595–7
Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993 May; 37: 1073–81
Stamm WE, Hooton TM. Management of urinary tract infections in adults. N Engl J Med 1993; 329: 1328–34
Rubin RH, Shapiro ED, Andriole VT, et al. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Clin Infect Dis 1992; 15 Suppl. 1: S216–227
Karachalios GN, Georgiopoulos AN, Nasopoulou-Papadimitriou DD. Value of single-dose Ciprofloxacin in the treatment of acute uncomplicated urinary tract infection in women. Drugs Exp Clin Res 1991; 17(10–11): 521–4
Raz R, Rottensterich E, Hefter H. Single-dose Ciprofloxacin in the treatment of uncomplicated urinary tract infection in women. Eur J Clin Microbiol 1989 Dec; 8: 1040–2
Iravani A, Tice AD, McCarty J, et al. Short-course Ciproflox treatment of acute uncomplicated urinary tract infection in women: the minimum effective dose. Arch Intern Med 1995 Mar 13; 155: 485–94
McCarty J, Echols RM, Tosiello RL, et al. Prospective, randomized, double-blind comparison of 100mg Ciprofloxacin (CIP) twice daily for 3 days, trimethoprim/sulfamethoxazole (T/S) 160/800 mg twice daily for 7 days’, and Ofloxacin (OFL) 200mg twice daily for 7 days in the treatment of patients with acute uncomplicated lower urinary tract infection [abstract no. 104]. In: 5th Symposium on New Quinolones; August 1994; Singapore. 1994
Kowalsky SF, Tosiello RL, Echols RM; et al. Prospective, randomized, double-blind comparison of 100mg Ciprofloxacin (CIP) twice daily for 3 days, trimethoprim/sulfamethoxazole (T/S) 160/800 mg twice daily for 7 days and nitrofurantoin (NTR) 100mg twice daily for 7 days in the treatment of patients with acute uncomplicated lower urinary tract infection [abstract no. 105]. In: 5th Symposium on New Quinolones; August 1994; Singapore. 1994
Cordon F, Auquer F, Gorina E, et al. Comparison of Ciprofloxacin (C) single dose (SD) vs. 3 day norfloxacin (N) in non-complicated urinary tract infections in female patients [abstract]. In: 7th European Congress of Clinical Microbiology and Infectious Diseases. 1995: 261
Guibert J. Acute cystitis in women: effectiveness of Ciprofloxacin versus pefloxacin given as a single oral dose [in French]. Presse Med 1995 Feb 11; 24: 304–8
Iravani A. Multicenter study of single-dose and multiple-dose fleroxacin versus Ciprofloxacin in the treatment of uncomplicated urinary tract infections. Am J Med 1993 Mar 22; 94 Suppl. 3A: 89–96
Cox CE. A comparison of the safety and efficacy of lome-floxacin and Ciprofloxacin in the treatment of complicated or recurrent urinary tract infections. Am J Med 1992 Apr 6; 92 Suppl. 4A: 82S–6S
Naber KG. Lomefloxacin versus norfloxacin versus Ciprofloxacin in the treatment of complicated urinary tract infections. Int J Antimicrob Agents 1992 Dec; 2: 33–7
Schaeffer AJ, Anderson RU. Efficacy and tolerability of norfloxacin vs. Ciprofloxacin in complicated urinary tract infection. Urology 1992 Nov; 40: 446–9
Cox CE. Brief report: sequential intravenous and oral Ciprofloxacin versus intravenous ceftazidime in the treatment of complicated urinary tract infections. Am J Med 1989 Nov 30; 87 Suppl. 5A: 157S–9S
Fang G, Brennen C, Wagener M, et al. Use of Ciprofloxacin versus use of aminoglycosides for therapy of complicated urinary tract infection: prospective, randomized clinical and pharmacokinetic study. Antimicrob Agents Chemother 1991 Sep; 35: 1849–55
Boerema JBJ, Willems FThC, Verheggen WJHM. Ciprofloxacin versus cotrimoxazole in the treatment of patients with complicated urinary tract infections. Drug Invest 1989 Oct; 1: 18–23
Chow AW, Hall CB, Klein JO, et al. Evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Clin Infect Dis 1992; 15 Suppl. 1: S62–88
Ball AP, Tillotson GS. Lower respiratory tract infection therapy-the role of Ciprofloxacin. J Int Med Res 1995; 23: 315–27
Thys JP, Jacobs F, Byl B. Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1991 Apr; 10: 304–15
Ball P, Tillotson G, Wilson R. Chemotherapy for chronic bronchitis: controversies. Presse Med 1995 Jan 21; 24: 189–94
Chodosh S. Use of quinolones for the treatment of acute exacerbations of chronic bronchitis. Am J Med 1991 Dec 30; 91: 93S–100S
Korner RJ, Reeves DS, MacGowan AP. Dangers of oral fluoroquinolone treatment in community acquired upper respiratory tract infections [see comments]. BMJ 1994 Jan 15; 308: 191–2
Davies BI, Maesen FPV. Quinolones in chest infections. Antimicrob Agents Chemother 1986; 18: 296–9
Byl B, Kaufman L, Jacobs F, et al. Ciprofloxacin vs comparative antibiotics in LRTI. A meta-analysis [abstract]. Drugs 1993; 45 Suppl. 3: 428–9
Hirata-Dulas CAI, Stein DJ, Guay DRR. A randomized study of Ciprofloxacin versus ceftriaxone in the treatment of nursing home-acquired lower respiratory tract infections. J Am Geriatr Soc 1991 Oct; 39: 979–85
Johnson R, Levine S, Traub S, et al. Prospective, controlled, double-blind, randomized study comparing the efficacy and safety of Ciprofloxacin with ceftriaxone in the treatment of hospitalized patients with acute bacterial pneumonia. Infect Dis Clin Pract. In press
Khan FA, Basir R. Sequential intravenous-oral administration of Ciprofloxacin vs ceftazidime in serious bacterial respiratory tract infections [see comments]. Chest 1989 Sep; 96: 528–37
Marklein G, German Fleroxacin Study Group. Fleroxacin vs. Ciprofloxacin in the empirical treatment of severe pneumonia: IV/oral switch regimen [abstract]. In: 7th European Congress of Clinical Microbiology and Infectious Diseases. 1995: 139
Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: results of a multi-center, randomized, double-blind trial comparing intravenous Ciprofloxacin with imipenem-cilastatin. Antimicrob Agents Chemother 1994 Mar; 38: 547–57
Medical Research Council. Definition and classification of chronic bronchitis for clinical and epidemiological purposes. Lancet 1965; 1: 775–9
Chmel H, Emmanuel G, Lie T, et al. A prospective, double-blind, randomized study comparing the efficacy and safety of low-dose Ciprofloxacin with ampicillin in the treatment of bronchitis. Diagn Microbiol Infect Dis 1990 Mar–Apr; 13: 149–51
Basran GS, Joseph J, Abbas AMA. Treatment of acute exacerbations of chronic obstructive airways disease — a comparison of amoxycillin and Ciprofloxacin. J Antimicrob Chemother 1990 Dec; 26 Suppl.F: 19–24
Cazzola M, Vinciguerra A, Beghi GF, et al. Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs Cefixime or Ciprofloxacin in bacterial exacerbation of chronic bronchitis. J Chemother 1995; 7: 432–41
Quenzer RW, Davis RL, Neidhart MM. Prospective randomized study comparing the efficacy and safety of Ciprofloxacin with Cefaclor in the treatment of patients with purulent bronchitis. Diagn Microbiol Infect Dis 1990 Mar–Apr; 13: 143–8
Chodosh S, Echols S, Kowalsky S, et al. A prospective, randomized, double-blind, comparative study of Ciprofloxacin (CIP) and cefuroxime axetil (CEF) for the treatment of acute bacterial exacerbations of chronic bronchitis (AECB) [abstract no. 166]. In: IDSA 33rd Annual Meeting: 1995 16–18 Sep: San Francisco, California. 1995: 58
Bensch G, Taglietti M. Once-daily Ceftibuten versus twice-daily Ciprofloxacin in acute exacerbation of chronic bronchitis [abstract]. Can J Infect Dis 1995 Jul; 6 Suppl.C: 269C
Catena E, Cesana M, Rufloxacin in AE of CBSG. 5-Day rufloxacin treatment versus 7-day Ciprofloxacin treatment in patients with acute exacerbations of chronic bronchitis: a randomised study. Clin Drug Invest 1995 Jun; 9: 334–43
Grossman RF, Beaupre A, LaForge J. A prospective randomised parallel single-blind comparison of oral Ciprofloxacin with oral cotrimoxazole in the treatment of respiratory tract infections in patients with chronic obstructive lung disease. Drug Invest 1994 Aug; 8: 110–7
Kosmidis J. A double-blind study of once-daily temafloxacin in the treatment of bacterial lower respiratory tract infections. J Antimicrob Chemother 1991 Dec; 28 Suppl.C: 73–9
Chodosh S. Temafloxacin compared with Ciprofloxacin in mild to moderate lower respiratory tract infections in ambulatory patients. A multicentre, double-blind, randomized study. Chest 1991 Dec; 100: 1497–502
Lindsay G, Scorer HJN, Carnegie CMD. Safety and efficacy of temafloxacin versus Ciprofloxacin in lower respiratory tract infections: a randomized, double-blind trial. J Antimicrob Chemother 1992 Jul; 30: 89–100
Klein GL, Heyd A, Echols R. Oral Ciprofloxacin vs cefuroxime axetil in acute bacterial sinusitis. A pilot study in adults [abstract]. Drugs 1993; 45 Suppl.3: 324
Heyd A, Echols R, Shan M, et al. Oral Ciprofloxacin (CIP) vs cefuroxime axetil (CA) in the treatment of acute sinusitis [abstract no. LM31]. In: Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco. 1995: 332
Legent F, Bordure P, Beauvillain C, et al. A double-blind comparison of Ciprofloxacin and amoxycillin/clavulanic acid in the treatment of chronic sinusitis. Chemotherapy 1994; 40 Suppl. 1: 8–15
Brooke I, Finegold SM. Bacteriology of chronic Otitis media. JAMA 1979; 241: 487–8
Rubin J, Yu VL. Malignant external Otitis: insights into pathogenisis, clinical manifestations, diagnosis, and therapy. Am J Med 1988; 85: 391–8
Fombeur JP, Barrault S, Koubbi G, et al. Study of the efficacy and safety of Ciprofloxacin in the treatment of chronic Otitis. Chemotherapy 1994; 40 Suppl. 1: 29–34
Legent F, Bordure P, Beauvillain C, et al. Controlled prospective study of oral Ciprofloxacin versus amoxycillin/clavulanic acid in chronic suppurative Otitis media in adults. Chemotherapy 1994; 40 Suppl. 1: 16–23
Gehanno P. Ciprofloxacin in the treatment of malignant external Otitis. Chemotherapy 1994; 40 Suppl. 1: 35–40
Sade J, Lang R, Goshen S, et al. Ciprofloxacin treatment of malignant external Otitis. Am J Med 1989 Nov 30; 87 Suppl. 5A: 138S–41S
Hoiby N, Pedersen SS, Jensen T, et al. Fluoroquinolones in the treatment of cystic fibrosis. Drugs 1993; 45 Suppl. 3: 98–101
Steen HJ, Scott EM, Stevenson MI, et al. Clinical and pharmacokinetic aspects of Ciprofloxacin in the treatment of acute exacerbations of Pseudomonas infection in cystic fibrosis patients. J Antimicrob Chemother 1989 Nov; 24: 787–95
Strandvik B, Hjelte L, Lindblad A, et al. Comparison of efficacy and tolerance of intravenously and orally administered Ciprofloxacin in cystic fibrosis patients with acute exacerbations of lung infection. Scand J Infect Dis Suppl. 1989; 60: 84–8
Rubip TT. Ciprofloxacin in the treatment of Pseudomonas infection in children with cystic fibrosis. Diagn Microbiol Infect Dis 1990 Mar–Apr; 13: 153–5
Bosso JA. Use of Ciprofloxacin in cystic fibrosis patients. Am J Med 1989 Nov 30; 87 Suppl. 5A: 123S–7S
Schaad UB, Wedgwood-Krucko J, Guenin K, et al. Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral Ciprofloxacin. Eur J Clin Microbiol 1989 Oct; 8: 858–65
Church D, Kanga J, Kuhn R. Prospective, double-blind, randomized comparison of Ciprofloxacin (CIP) vs ceftazidime/tobramycin (C/T) in the treatment of pediatric cystic fibrosis [abstract no. LM30]. In: Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17–21; San Francisco. 1995: 332.
Valerius NH, Koch C, Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991 Sep 21; 338: 725–6
Sheldon CD, Assoufi BK, Hodson ME. Regular three monthly oral Ciprofloxacin in adult cystic fibrosis patients infected with Pseudomonas aeruginosa. Respir Med 1993 Nov; 87: 587–93
Szaff M, Hoiby N, Flensborg EW. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand 1983; 72: 651–7
Pedersen SS, Jensen T, Hoiby N, et al. Management of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients. Acta Paediatr Scand 1987; 76: 955–61
Goodman LJ, Trenholme GM, Kaplan RL, et al. Empiric antimicrobial therapy of domestically acquired acute diarrhea in urban adults. Arch Intern Med 1990 Mar; 150: 541–6
Salam I, Katelaris P, Leigh-Smith S, et al. Randomised trial of single-dose Ciprofloxacin for travellers’ diarrhoea. Lancet 1994 Dec 3; 344: 1537–9
Taylor DN, Sanchez JL, Candler W, et al. Treatment of travelers’ diarrhea: Ciprofloxacin plus loperamide compared with Ciprofloxacin alone. A placebo-controlled, randomized trial. Ann Intern Med 1991 May 1; 114: 731–4
Petruccelli BP, Murphy GS, Sanchez JL, et al. Treatment of traveler’s diarrhea with Ciprofloxacin and loperamide. J Infect Dis 1992 Mar; 165: 557–60
Rademaker CMA, Hoepelman IM, Wolfhagen MJHM, et al. Results of a double-blind placebo-controlled study using Ciprofloxacin for prevention of travelers’ diarrhea. Eur J Clin Microbiol 1989 Aug; 8: 690–4
DuPont HL. Travellers’ diarrhoea. Which antimicrobial?. Drugs 1993; 45: 910–7
Obot EG, DuPont HL. Current approach to the treatment of travellers’ diarrhoea. Int J Antimicrob Agents 1993 Sep; 3: 97–103
Moss PJ, Read RC. Empiric antibiotic therapy for acute infective diarrhoea in the developed world. J Antimicrob Chemother 1995 Jun; 35: 903–13
Wiström J, Norrby R. Antibiotic prophylaxis of travellers’ diarrhoea. Scand J Infect Dis 1990; 22 Suppl. 70: 111–29
Murphy GS, Bodhidatta L, Echeverria P, et al. Ciprofloxacin and loperamide in the treatment of bacillary dysentery. Ann Intern Med 1993 Apr 15; 118: 582–6
Bennish ML, Salam MA, Haider R. Therapy for shigellosis. II. Randomized, double-blind comparison of Ciprofloxacin and ampicillin. J Infect Dis 1990 Sep; 162: 711–6
Bennish ML, Salam MA, Khan WA. Treatment of shigellosis: III. Comparison of one- or two-dose Ciprofloxacin with standard 5-day therapy. A randomized, blinded trial. Ann Intern Med 1992 Nov 1; 117: 727–34
Wilcox MH, Spencer RC. Quinolones and salmonella gastroenteritis. J Antimicrob Chemother 1992 Aug; 30: 221–8
Pichler HET, Dirild G, Stickler K, et al. Clinical efficacy of Ciprofloxacin compared with placebo in bacterial diarrhea. Am J Med 1987; 82 Suppl. 4A: 329–32
Sánchez C, García-Restoy E, Garau J, et al. Ciprofloxacin and trimethoprim-sulfamethoxazole versus placebo in acute uncomplicated Salmonella enteritis: a double-blind trial. J Infect Dis 1993 Nov; 168: 1304–7
Lightfoot NF, Ahmad F, Cowden J. Management of institutional outbreaks of salmonella gastroenteritis. J Antimicrob Chemother 1990 Dec; 26 Suppl.F: 37–46
Ahmad F, Bray G, Prescott RWG, et al. Use of Ciprofloxacin to control a salmonella outbreak in a long-stay psychiatric hospital. J Hosp Infect 1991 Mar; 17: 171–8
Dyson C, Ribeiro CD, Westmoreland D. Large scale use of Ciprofloxacin in the control of a salmonella outbreak in a hospital for the mentally handicapped. J Hosp Infect 1995 Apr; 29: 287–96
Neill MA, Opal SM, Heelan J, et al. Failure of Ciprofloxacin to eradicate convalescent fecal excretion after acute salmonellosis: experience during an outbreak in health care workers. Ann Intern Med 1991 Feb 1; 114: 195–9
Akalin HE. Role of quinolones in the treatment of diarrhoeal diseases. Drugs 1995; 49 Suppl. 2: 128–31
Corrado ML, DuPont HL, Cooperstock M, et al. Evaluation of new anti-infective drugs for the treatment of typhoid fever. Clin Infect Dis 1992; 15 Suppl.1: S236–40
DuPont HL. Quinolones in Salmonella typhi infection. Drugs 1993; 45 Suppl. 3: 119–24
Mandai BK. Modern treatment of typhoid fever. J Infect 1991; 22: 1–4
Ramirez CA, Bran JL, Mejia CR, et al. Open, prospective study of the clinical efficacy of Ciprofloxacin. Antimicrob Agents Chemother 1985; 28: 128–32
Ippolito A, La GG, Matarrese M, et al. Ciprofloxacin in the treatment of gastrointestinal infections [in Italian]. Minerva Med 1991 Apr; 82: 181–8
Alam MN, Haq SA, Das KK, et al. Efficacy of Ciprofloxacin in enteric fever: comparison of treatment duration in sensitive and multidrug-resistant Salmonella. Am J Trop Med Hyg 1995; 53: 306–11
Uwaydah AK, Al Soub H, Matar I. Randomized prospective study comparing two dosage regimens of Ciprofloxacin for the treatment of typhoid fever. J Antimicrob Chemother 1992 Nov; 30: 707–11
Chew SK, Monteiro EHA, Lim YS. A 7-day course of Ciprofloxacin for enteric fever. J Infect 1992 Nov; 25: 267–71
Stanley PJ, Flegg PJ, Mandal BK, et al. Open study of Ciprofloxacin in enteric fever. J Antimicrob Chemother 1989 May; 23: 789–91
Limson BM. Short course quinolone therapy of typhoid fever in developing countries. Drugs 1995; 49 Suppl. 2: 136–8
Nelwan RHH, Hendarwanto, Zulkarnain I, et al. A comparative study of short course Ciprofloxacin therapy in typhoid and paratyphoid fever. Drugs 1995; 49 Suppl. 2: 463–5
Gotuzzo E, Carrillo C. Mini review: quinolones in typhoid fever. Infect Dis Clin Pract 1994; 3: 345–51
Morelli G, Mazzoli S, Tortoli E, et al. Fluoroquinolones versus chloramphenicol in the therapy of typhoid fever: a clinical and microbiological study. Curr Ther Res 1992 Oct; 52: 532–42
Singh CP, Singh N, Brar GK, et al. Efficacy of Ciprofloxacin and norfloxacin in multidrug resistant enteric fever in adults. J Indian Med Assoc 1993 Jun; 91: 156–7
Limson BM, Littaua RT. Comparative study of Ciprofloxacin versus co-trimoxazole in the treatment of Salmonella enteric fever [letter]. Infection 1989 Mar–Apr; 17: 105–6
Flores GR. Pharmacological treatment of typhoid fever: a comparative study of Ciprofloxacin vs. trimethoprim-sulfamethoxazole. Invest Med Int 1991 Mar; 17: 185–8
Wallace MR, Yousif AA, Mahroos GA, et al. Ciprofloxacin versus ceftriaxone in the treatment of multiresistant typhoid fever. Eur J Clin Microbiol Infect Dis 1993 Dec; 12: 907–10
Dutta P, Rasaily R, Saha MR, et al. Ciprofloxacin for treatment of severe typhoid fever in children. Antimicrob Agents Chemother 1993 May; 37: 1197–9
Koul PA, Wani JI, Wahid A. Ciprofloxacin in multiresistant enteric fever in pregnancy. Lancet 1995; 346: 307–8
Ferreccio C, Morris Jr JG, Valdivieso C, et al. Efficacy of ciprofloxacin in the treatment of chronic typhoid carriers. J Infect Dis 1988 Jun; 157: 1235–9
Ramamurthy T, Garg S, Sharms R, et al. Emergence of a novel strain of Vibrio cholerae with epidemic potential in southern and eastern India. Lancet 1993; 341: 703–4
Corrado ML, DuPont HL, Cooperstock M, et al. Evaluation of new anti-infective drugs for the treatment of cholera. Clin Infect Dis 1992; 15 Suppl. 1: S241–3
Gotuzzo E, Seas C, Echevarría J, et al. Ciprofloxacin for the treatment of cholera: a randomized, double-blind, controlled clinical trial of a single daily dose in Peruvian adults. Clin Infect Dis 1995 Jun; 20: 1485–90
Khan WA, Begum M, Salam MA, et al. Comparative trial of five antimicrobial compounds in the treatment of cholera in adults. Trans R Soc Trop Med Hyg 1995 Jan–Feb; 89: 103–6
Khan WA, Seas C, Khan EH, et al. Randomized, double-blinded comparison of single dose Ciprofloxacin with single dose doxycycline in the treatment of Vibrio cholerae 0139 (Bengal) infection [abstract]. In: 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1994: 245
Echevarria J, Seas C, Carillo C, et al. Efficacy and tolerability of Ciprofloxacin prophylaxis in adult household contacts of patients with cholera. Clin Infect Dis 1995 Jun; 20: 1480–4
Gentry LO. Review of quinolones in the treatment of infections of the skin and skin structure. J Antimicrob Chemother 1991 Dec; 28 Suppl.C: 97–110
Parish LC, Witkowski JA, Jungkind DL, et al. Treatment of cutaneous infections. Worldwide experience with Ciprofloxacin. Int J Dermatol 1988 Mar; 27: 131–3
Gentry LO, Ramirez-Rhonda CH, Rodriguez NE, et al. Oral Ciprofloxacin vs parenteral cefotaxime in the treatment of difficult skin and skin structure infections. Arch Intern Med 1989 Nov; 149: 2579–83
Tice AD, Marsh PK, Craven PC. Comparison of intravenous Ciprofloxacin with ceftazidime in the treatment of serious soft tissue infections. Diagn Microbiol Infect Dis 1990 Mar–Apr; 13: 165–7
Dominguez J, Palma F, Vega ME, et al. Brief report: prospective, controlled, randomized non-blind comparison of intravenous/oral Ciprofloxacin with intravenous ceftazidime in the treatment of skin or soft-tissue infections. Am J Med 1989 Nov 30; 87 Suppl. 5A: 136S–7
Gentry LO, Koshdel A. Intravenous/oral Ciprofloxacin versus intravenous ceftazidime in the treatment of serious gram-negative infections of the skin and skin structure. Am J Med 1989 Nov 30; 87 Suppl. 5A: 132–5
McCarty J. Lomefloxacin vs Ciprofloxacin in the treatment of non-necrotising skin and skin structure infections [abstract]. Drugs 1993; 45 Suppl.3: 387
Monroe A. Lomefloxacin vs Ciprofloxacin in the treatment of non-necrotising skin and skin structure infections [abstract]. Drugs 1993; 45 Suppl.3: 390
Mader JT, Norden C, Nelson JD, et al. Evaluation of new anti-infective drugs for the treatment of osteomyelitis in adults. Clin Infect Dis 1992; 15 Suppl.1: S155–61
Swedish Study Group. Therapy of acute and chronic Gram-negative osteomyelitis with Ciprofloxacin. J Antimicrob Chemother 1988; 22: 221–8
Yamaguti A, Trevisanello C, Lobo IMF, et al. Oral Ciprofloxacin for treatment of chronic osteomyelitis. Int J Clin Pharmacol Res 1993; 13 (2): 75–9
MacGregor RR, Graziani AL, Esterhai JL. Oral Ciprofloxacin for osteomyelitis. Orthopedics 1990 Jan; 13: 55–60
Hoogkamp-Korstanje JA, van-Bottenburg HA, van-Bruggen J, et al. Treatment of chronic osteomyelitis with Ciprofloxacin. J Antimicrob Chemother 1989 Mar; 23: 427–32
Dan M, Siegman-Igra Y, Pitlik S, et al. Oral Ciprofloxacin treatment of Pseudomonas aeruginosa osteomyelitis. Antimicrob Agents Chemother 1990 May; 34: 849–52
Gentry LO, Rodriguez GG. Oral Ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis. Antimicrob Agents Chemother 1990 Jan; 34: 40–3
Gentry LO, Rodriguez-Gomez G, Roniker B. The safety and efficacy of lomefloxacin and Ciprofloxacin in the treatment of acute and chronic osteomyelitis [abstract]. In: 5th International Symposium on New Quinolones. 1994: 158
Hughes WT, Pizzo PA, Wade JC, et al. Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Clin Infect Dis 1992; 15 Suppl. 1: S206–15
Bayston KF, Want S, Cohen J. A prospective, randomized comparison of ceftazidime and Ciprofloxacin as initial empiric therapy in neutropenic patients with fever. Am J Med 1989 Nov 30; 87 Suppl. 5A: 269–73
Verhagen C, De Pauw B, Donnelly J, et al. Ciprofloxacin versus ceftazidime monotherapy in the empirical treatment of febrile neutropenic patients [abstract]. In: 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. 1993: 308
Meunier F, Zinner SH, Gaya H, et al. Prospective randomized evaluation of Ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. Antimicrob Agents Chemother 1991 May; 35: 873–8
Johnson PRE, Liu Yin JA, Tooth JA. A randomized trial of high-dose Ciprofloxacin versus azlocillin and netilmicin in the empirical therapy of febrile neutropenic patients. J Antimicrob Chemother 1992 Aug; 30: 203–14
Philpott-Howard JN, Barker KF, Wade JJ, et al. Randomized multicentre study of Ciprofloxacin and azlocillin versus genta-micin and azlocillin in the treatment of febrile neutropenic patients. J Antimicrob Chemother 1990 Dec; 26 Suppl F: 89–99
Flaherty JP, Waitley D, Edlin B, et al. Multicenter, randomized trial of Ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients. Am J Med 1989 Nov 30; 87 Suppl. 5A: 278–83
Hyatt DS, Rogers TRF, McCarthy DM. A randomized trial of Ciprofloxacin plus azlocillin versus netilmicin plus azlocillin for the empirical treatment of fever in neutropenic patients. J Antimicrob Chemother 1991 Aug; 28: 324–6
Chan CC, Oppenheim BA, Anderson H, et al. Randomized trial comparing Ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for empiric treatment of fever in neutropenic patients. Antimicrob Agents Chemother 1989 Jan; 33: 87–91
Kelsey SM, Collins PW, Delord C, et al. A randomized study of teicoplanin plus Ciprofloxacin versus gentamicin plus piperacillin for the empirical treatment of fever in neutropenic patients. Br J Haematol 1990 Dec; 76 Suppl.2: 10–3
Kelsey SM, Wood ME, Shaw E. A comparative study of intravenous Ciprofloxacin and benzylpenicillin versus netilmicin and piperacillin for the empirical treatment of fever in neutropenic patients. J Antimicrob Chemother 1990 Jan; 25: 149–57
Martino P, Micozzi A, Gentile G, et al. Piperacillin plus amikacin vs. piperacillin plus amikacin plus teicoplanin for empirical treatment of febrile episodes in neutropenic patients receiving quinolone prophylaxis. Clin Infect Dis 1992; 15: 290–4
Fenu S, Raccah R, Santilli S, et al. Treatment of febrile episodes in neutropenic leukemic patients with the antibiotic combinations piperacillin or ceftazidime plus amikacin: results of a randomized study. Chemioterapia 1988; 7: 323–6
Nováková I, Donnelly P, de Pauw B. Amikacin plus piperacillin versus ceftazidime as initial therapy in granulocytopenic patients with presumed bacteremia. Scand J Infect Dis 1991; 22: 705–11
De Pauw BE, Deresinski SC, Feld R, et al. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. Ann Intern Med 1994; 120: 834–44
Leyland MJ, Bayston KF, Cohen J, et al. A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies. J Antimicrob Chemother 1992; 30: 843–54
Lim SH, Smith MP, Goldstone AH, et al. A randomized prospective study of ceftazidime and Ciprofloxacin with or without teicoplanin as an empiric antibiotic regimen for febrile neutropenic patients. Br J Haematol 1990 Dec; 76 Suppl.2: 41–4
Rubenstein EB, Rolston K, Benjamin RS, et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 1993 Jun 1; 71: 3640–6
Rolston KVI, Rubenstein EB, Elting LS, et al. Ambulatory management of febrile episodes in low-risk neutropenic patients [abstract no. LM38]. In: Abstracts of the 35th Inter-science Conference on Antimicrobial Agents and Chemotherapy. San Francisco. 1994: 333
Velasco E, Costa MA, Martins CA, et al. Randomized trial comparing oral ciprofloxacin plus penicillin V with amikacin plus carbenicillin or ceftazidime for empirical treatment of febrile neutropenic cancer patients. Am J Clin Oncol Cancer Clin Trials 1995; 18: 429–35
Del Favero A, Menichetti F. The new fluorinated quinolones for antimicrobial prophylaxis in neutropenic cancer patients. Eur J Cancer 1993; 29A Suppl.1: S2–6
Cruciani M, Rampazzo R, Lazzarini L, et al. Fluoroquinolones prophylaxis of bacterial infections in neutropenic patients: a meta-analysis [abstract]. In: 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1995: 333
Lew MA, Kehoe K, Ritz J, et al. Prophylaxis of bacterial infections with Ciprofloxacin in patients undergoing bone marrow transplantation. Transplantation 1991 Mar; 51: 630–6
Verhoef J, Rozenberg-Arska M, Dekker A. Prevention of infection in the neutropenic patient. Rev Infect Dis 1989 Nov–Dec; 11 Suppl.7: S1545–50
Arning M, Wolf HH, Aul C, et al. Infection prophylaxis in neutropenic patients with acute leukaemia — a randomized, comparative study with Ofloxacin, Ciprofloxacin and co-trimoxazole/colistin. J Antimicrob Chemother 1990 Nov; 26 Suppl.D: 137–42
Dekker AW, Rozenberg-Arska M, Verhoef J. Infection prophylaxis in acute leukemia: a comparison of Ciprofloxacin with trimethoprim-sulfamethoxazole and Colistin. Ann Intern Med 1987; 106: 7–11
Lew MA, Kehoe K, Ritz J, et al. Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. J Clin Oncol 1995 Jan; 13: 239–50
Donnelly JP, Maschmeyer G, Daenen S. Selective oral antimicrobial prophylaxis for the prevention of infection in acute leukaemia — ciprofloxacin versus co-trimoxazole plus Colistin. Eur J Cancer 1992 Apr–May; 28A: 873–8
GIMEMA Infection Program. Prevention of bacterial infection in neutropenic patients with hematologic malignancies. A randomized, multicenter trial comparing norfloxacin with Ciprofloxacin. Ann Intern Med 1991 Jul 1; 115: 7–12
D’Antonio D, Piccolomini R, lacone A, et al. Comparison of Ciprofloxacin, Ofloxacin and Pefloxacin for the prevention of the bacterial infection in neutropenic patients with haemato-ogical malignancies. J Antimicrob Chemother 1994 Apr; 33: 837–44
Ball P. Editorial response: Is resistant Escherichia coli bacteremia an inevitable outcome for neutropenic patients receiving a fluoroquinolone as prophylaxis?. Clin Infect Dis 1995; 20: 561–3
Working Party of the British Society for Antimicrobial Chemotherapy. Diagnosis and management of peritonitis in the management of continuous ambulatory peritoneal dialysis. Lancet 1987 Apr 11; 1: 845–8
Ludlam H, Dryden M, Barton I, et al. Short course Ciprofloxacin therapy for CAPD peritonitis [letter]. J Antimicrob Chemother 1990 Jul; 26: 162–4
Ludlam HA, Barton I, White L, et al. Intraperitoneal Ciprofloxacin for the treatment of peritonitis in patients receiving continuous ambulatory peritoneal dialysis. J Antimicrob Chemother 1990 May; 25: 843–51
Dryden MS, Wing AJ, Phillips I. Low dose intraperitoneal Ciprofloxacin for the treatment of peritonitis in patients receiving continuous ambulatory peritoneal dialysis (CAPD). J Antimicrob Chemother 1991 Jul; 28: 131–9
Pérez Fontain M, Rosales M, Fernández F, et al. Treatment of CAPD peritonitis with Ciprofloxacin — long term results [in Spanish]. Nefrologia 1993; 13 (2): 149–54
Fleming LW, Phillips G, Stewart WK. Oral Ciprofloxacin in the treatment of peritonitis in patients on continuous ambulatory peritoneal dialysis. J Antimicrob Chemother 1990 Mar; 25: 441–8
Waite MN, Johnson MD, Webster NR, et al. Poor response to oral Ciprofloxacin in the treatment of peritoneal dialysis-related peritonitis [abstract]. Pharmacotherapy 1992; 12 (3): 253–4
Cheng IK, Chan CY, Wong WT, et al. A randomized prospective comparison of oral versus intraperitoneal Ciprofloxacin as the primary treatment of peritonitis complicating continuous ambulatory peritoneal dialysis. Perit Dial Int 1993; 13 Suppl. 2: S351–4
Nye KJ, Gibson SP, Nwosu AC, et al. Single-dose intraperitoneal vancomycin and oral Ciprofloxacin for the treatment of peritonitis in CAPD patients: preliminary report. Perit Dial Int 1993; 13 (1): 59–60
Bennett-Jones DN, Russell GI, Barrett A. A comparison between oral Ciprofloxacin and intra-peritoneal vancomycin and gentamicin in the treatment of CAPD peritonitis. J Antimicrob Chemother 1990 Dec; 26 Suppl.F: 73–6
Tapson JS, Orr KE, George JC, et al. A comparison between oral Ciprofloxacin and intraperitoneal vancomycin and netilmicin in CAPD peritonitis. J Antimicrob Chemother 1990 Dec; 26 Suppl.F: 63–71
Friedland JS, Iveson TJ, Fraise AP, et al. A comparison between intraperitoneal Ciprofloxacin and intraperitoneal vancomycin and gentamicin in the treatment of peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD). J Antimicrob Chemother 1990 Dec; 26 Suppl.F: 77–81
Solomkin JS, Hemsell DL, Sweet R, et al. Evaluation of new anti-infective drugs for the treatment of intraabdominal infections. Clin Infect Dis 1992; 15 Suppl.1: S33–42
Yoshioka K, Youngs DJ, Keighley MRB. A randomised prospective controlled study of Ciprofloxacin with metronidazole versus amoxicillin/clavulanic acid with metronidazole in the treatment of intra-abdominal infection. Infection 1991 Jan–Feb; 19: 25–9
Hoogkamp-Korstanje JAA. Ciprofloxacin vs. cefotaxime regimens for the treatment of intra-abdominal infections. Infection 1995; 23: 278–82
Solomkin JS, Reinhart HH, Dellinger EP, et al. Results of a randomized trial comparing sequential intravenous/oral treatment with Ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. Ann Surg. In press
Karachalios GN, Zografos G, Patrikakos V. Biliary tract infections treated with ciprofloxacin. Infection 1993 Jul–Aug; 21: 262–4
Sung JJY, Lyon DJ, Suen R, et al. Intravenous ciprofloxacin as treatment for patients with acute suppurative cholangitis: a randomized, controlled clinical trial. J Antimicrob Chemother 1995 Jun; 35: 855–64
Hemsell DL, Solomkin JS, Sweet R, et al. Evaluation of new anti-infective drugs for the treatment of acute pelvic infections in hospitalized women. Clin Infect Dis 1992; 15 Suppl.1: S43–52
Sweet RL, Bartlett JG, Hemsell DL, et al. Evaluation of new anti-infective drugs for the treatment of acute pelvic inflammatory disease. Clin Infect Dis 1992; 15 Suppl.1: S53–61
Thadepalli H, Mathai D, Scotti R, et al. Ciprofloxacin mono-therapy for acute pelvic infections: a comparison with Clindamycin plus gentamicin. Obstet Gynecol 1991 Oct; 78: 696–702
Crombleholme WR, Schachter J, Ohm-Smith M, et al. Efficacy of single-agent therapy for the treatment of acute pelvic inflammatory disease with ciprofloxacin. Am J Med 1989 Nov 30; 87 Suppl. 5a: 142S–7S
Fischbach F, Deckardt R, Graeff H. Ciprofloxacin/metronidazole vs. cefoxitin/doxycycline: comparison of two antibiotic regimens in the treatment of PID [in German]. Geburtshilfe Frauenheilkd 1994 Jun; 54: 337–40
Heinonen PK, Teisala K, Miettinen A, et al. A comparison of ciprofloxacin with doxycycline plus metronidazole in the treatment of acute pelvic inflammatory disease. Scand J Infect Dis Suppl 1989; 60: 66–73
Apuzzio JJ, Stankiewicz R, Ganesh V, et al. Comparison of parenteral ciprofloxacin with clindamycin-gentamicin in the treatment of pelvic infection. Am J Med 1989 Nov 30; 87 Suppl. 5A: 148S–51S
Maccato ML, Faro S, Martens MG, et al. Ciprofloxacin versus gentamicin/clindamycin for postpartum endometritis. J Reprod Med 1991 Dec; 36: 857–61
Brown AE, Smith G. Treatment of sepsis in patients with neoplastic diseases with intravenous ciprofloxacin. Am J Med 1989 Nov 30; 87 Suppl. 5A: 266S–8
Bouza E, Diaz-Lopez MD, Bernaldo de QJCL. Ciprofloxacin in patients with bacteremic infections. Am J Med 1989 Nov 30; 87 Suppl. 5A: 228S–31S
Skoutelis A, Chrysanthopoulos C, Starakis J, et al. Treatment of gram-negative aerobic bacteremia with sequential intravenous to oral Ciprofloxacin. Infect Dis Clin Pract 1994 Sep–Oct; 3: 352–6
Gangji D, Jacobs F, De Jonckheer J, et al. Brief report: randomized study of intravenous versus sequential intravenous/oral regimen of Ciprofloxacin in the treatment of gram-negative septicemia. Am J Med 1989 Nov 30; 87 Suppl. 5A: 206–8
Caballero M, Bonora V, Calabuig JR, et al. Clinical and microbiological comparison of sequential IV/PO Ciprofloxacin (CIP) vs parenteral cefotaxime (CEF) in patients with sepsis [abstract]. In: 7th European Congress of Clinical Microbiology and Infectious Diseases. 1995: 218
Christensen MM, Nielsen KT, Knes J. Brief report: single-dose preoperative prophylaxis in transurethral surgery. Am J Med 1989 Nov 30; 87 Suppl. 5A: 258S–60S
Cox CE. Comparison of intravenous Ciprofloxacin and intravenous cefotaxime for antimicrobial prophylaxis in transurethral surgery. Am J Med 1989 Nov 30; 87 Suppl. 5A: 252S–4S
Gombert ME, DuBouchet L, Aulicino TM, et al. Brief report: intravenous Ciprofloxacin versus cefotaxime prophylaxis during transurethral surgery. Am J Med 1989 Nov 30; 87 Suppl. 5A: 250–1
Klimberg I, Echols R, Whalen E, et al. Prospective, randomized double-blind comparison of single-dose oral (PO) Ciprofloxacin (CIP) vs single-dose intravenous (IV) cefotaxime (CTX) vs placebo (PLA) for antimicrobial prophylaxis during transurethral (TUR) surgery [abstract no. 2002]. Can J Infect Dis 1995; 6 Suppl. C: 343C
Kujath P. Brief report: antibiotic prophylaxis in biliary tract surgery. Ciprofloxacin versus ceftriaxone. Am J Med 1989 Nov 30; 87 Suppl. 5A: 255–7
Mehal WZ, Culshaw KD, Tillotson GS, et al. Antibiotic prophylaxis for ERCP: a randomised clinical trial of ciprofloxacin versus cefuroxime [abstract]. Gastroenterology 1993 Apr; 104 Suppl.: A370
Mehal WZ, Culshaw KD, Tillotson GS, et al. Antibiotic prophylaxis for ERCP: a randomized clinical trial comparing ciprofloxacin and cefuroxime in 200 patients at high risk of cholangitis. Eur J Gastroenterol Hepatol 1995; 7: 841–5
Alveyn CG, Robertson DAF, Wright R, et al. Prevention of sepsis following endoscopic retrograde cholangiopancreatography. J Hosp Infect 1991 Sep; 19 Suppl. C: 65–70
Offer C, Weuta H, Bodner E. Efficacy of perioperative prophylaxis with ciprofloxacin or cefazolin in colorectal surgery. Infection 1988; 16 Suppl.1: S46–7
Gortz G, Boese-Landgraf J, Hopfenmuller W, et al. Ciprofloxacin as single-dose antibiotic prophylaxis in colorectal surgery. Results of a randomized, double-blind trial. Diagn Microbiol Infect Dis 1990 Mar–Apr; 13: 181–5
McArdle CS, Morran CG, Pettit L, et al. Value of oral antibiotic prophylaxis in colorectal surgery. Br J Surg 1995; 82: 1046–8
Risberg B, Drott C, Dalman P, et al. Oral Ciprofloxacin versus intravenous cefuroxime as prophylaxis against postoperative infection in vascular surgery: a randomised double-blind, prospective multicentre study. Eur J Vase Surg 1995; 10: 346–51
Echols RM, Heyd A, O’Keeffe BJ, et al. Single-dose Ciprofloxacin for the treatment of uncomplicated gonorrhea: a worldwide summary. Sex Transm Dis 1994 Nov–Dec; 21: 345–52
Leow YH, Chan RKW, Cheong LL, et al. Comparing the efficacy of pefloxacin and Ciprofloxacin in the treatment of acute uncomplicated gonococcal Urethritis in males. Ann Acad Med Singapore 1995; 24: 515–8
Moi H, Jean C. Comparative efficacy and safety of Sparfloxacin versus Ciprofloxacin in the treatment of acute gonococcal Urethritis in males: a multicentre, international, double-blind randomised study of 238 patients [abstract]. In: 5th International Symposium on New Quinolones. 1994: 144
Fong IW, Linton W, Simbul M, et al. Treatment of nongonococcal Urethritis with Ciprofloxacin. Am J Med 1987; 82 Suppl. 4: 311–6
Hooton TM, Rogers ME, Medina TG, et al. Ciprofloxacin comared with doxycycline for nongonococcal Urethritis. Ineffectiveness against Chlamydia trachomatis due to relapsing infection. JAMA 1990 Sep 11; 264: 1418–21
Behets FM-T, Liomba G, Lule G, et al. Sexually transmitted diseases and human immunodeficiency virus control in Malawi: a field study of genital ulcer disease. J Infect Dis 1995 Feb; 171: 451–5
Ballard RC, Radebe F, Mampuru M, et al. A comparison of ofloxacin and ciprofloxacin in the treatment of chancroid [abstract]. Sex Transm Dis 1994 Mar–Apr; 21 Suppl.: S135
Bodhidatta L, Taylor DN, Chitwarakorn A, et al. Evaluation of 500- and 1,000-mg doses of ciprofloxacin for the treatment of chancroid. Antimicrob Agents Chemother 1988 May; 32: 723–5
Traisupa A, Wongba C, Tesavibul P. Efficacy and safety of a single dose therapy of a 500 mg ciprofloxacin tablet in chancroid patients. Infection 1988; 16 Suppl.1: S44–5
Naamara W, Plummer FA, Greenblatt RM, et al. Treatment of chancroid with ciprofloxacin: a prospective randomized clinical trial. Am J Med 1987; 82: 317–20
Bogaerts J, Kestens L, Martinez TW, et al. Failure of treatment for chancroid in Rwanda is not related to human immunodeficiency virus infection: in vitro resistance of Haemophilus ducreyi to trimethoprim-sulfamethoxazole. Clin Infect Dis 1995 Apr; 20: 924–30
Schulte JM, Schmid GP. Recommendations for treatment of chancroid, 1993. Clin Infect Dis 1995 Apr; 20 Suppl. 1: S39–46
Kubin R. Safety and efficacy of ciprofloxacin in paediatric patients — review. Infection 1993 Nov–Dec; 21: 413–21
Schaad UB, Salam MA, Aujard Y, et al. Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commision. Pediatr Infect Dis J 1995; 14: 1–9
Balinsky W, Nesbitt S. Cost-effectiveness of outpatient antibiotics: a review of the literature. Am J Med 1987; 96: 102–9
Guay DR. Sequential antimicrobial therapy: a realistic approach to cost containment?. PharmacoEconomics 1993; 3: 341–4
Quintiliani R, Cooper BW, Briceland LL, et al. Economic impact of streamlining antibiotic administration. Am J Med 1987; 82 Suppl. 4A: 391–4
Frighetto L, Nickoloff D, Martinusen SM. Intravenous-to-oral stepdown program: four years of experience in a large teaching hospital. Ann Pharmacother 1992 Nov; 26: 1447–51
Balfour JA, Faulds D. Oral ciprofloxacin. A pharmacoeconomic evaluation of its use in the treatment of serious infections. PharmacoEconomics 1993 May; 3: 398–421
Parker SE, Davey PG. Pharmacoecnomics of intravenous drug administration. PharmacoEconomics 1992; 1: 103–15
Fliegelman RM, Mattingly PM, Dempsey CL, et al. Economic impact of oral ciprofloxacin following standard intravenous therapy. Diagn Microbiol Infect Dis 1990 Mar–Apr; 13: 187–9
Paladino JA, Sperry HE, Backes JM, et al. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. Am J Med 1991 Nov; 91: 462–70
Guay DR, Peterson PK, Stein DJ, et al. Cost comparison of ciprofloxacin versus cefamandole [letter]. DICP 1989 Jan; 23: 92–3
Paladino JA. Pharmacoeconomic comparison of sequential IV/oral ciprofloxacin versus ceftazidime in the treatment of nosocomial pneumonia. Can J Hosp Pharm 1995; 48: 276–83
Graham E, Whalen E, Smith ME, et al. Comparison of costs between ciprofloxacin and imipenem for the treatment of severe pneumonia in hospitalized patients [abstract]. Pharmacotherapy 1994 May–Jun; 14: 370–1
Caldwell J, Singh S, Johnson R. Pattern of subsequent infection and antibiotic use following initial treatment with Ciprofloxacin versus imipenem for nosocomial pneumonia [abstract no. M49]. In: Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1994 Oct 4–7; Orlando. 1995: 245
Cooke J, Cairns CJ, Tillotson GS, et al. Comparative clinical, microbiologic, and economic audit of the use of oral ciprofloxacin and parenteral antimicrobials. Ann Pharmacother 1993 Jun; 27: 785–9
Goff DA, Sierawski SJ, Gabriel MJ, et al. Evaluation and cost analysis of an interdisciplinary ciprofloxacin streamlining program [abstract]. Pharmacotherapy 1995 Jan–Feb; 15: 116
Goldman MP. Ciprofloxacin drug utilization review and prospective drug use evaluation. DICP 1990 Jan; 24: 82–6
Schlicht JR, Porter CK, Weber DR, et al. Drug use evaluation of intravenous ciprofloxacin: changing prescribing practices through education. PT 1994 Dec; 19: 1120–7
Grasela JTH, Paladino JA, Schentag JJ, et al. Clinical and economic impact of oral ciprofloxacin as follow-up to parenteral antibiotics. DICP 1991 Jul–Aug; 25: 857–62
Marchbanks CR, Graham KK, Barnes J, et al. Pharmacoepidemiology of ciprofloxacin: analysis of use patterns and cost impact. Pharmacotherapy 1991 Jan–Feb; 11: 50–5
Powers T, Bingham DH. Clinical and economic effect of ciprofloxacin as an alternative to injectable antimicrobial therapy. Am J Hosp Pharm 1990 Aug; 47: 1781–4
Dydek GJ, Souney PF, Matthews SJ. DUE of ciprofloxacin in the treatment of urinary tract infections in hospitalized patients. Hosp Formul 1992 Feb; 27: 185–91
Okpara AU, Maswoswe JJ, Stewart K. Criteria-based antimicrobial IV to oral conversion program. Formulary 1995 Jun; 30: 343–8
Barriere SL. Efficacy and cost-effectiveness of oral ciprofloxacin. PharmacoEconomics 1992 Feb; 1: 146–7
Schacht P, Arcieri G, Hullmann R. Safety of oral Ciprofloxacin. An update based on clinical trial results. Am J Med 1989 Nov 30; 87 Suppl. 5A: 98S–102S
Inman W, Kubota K, Pearce G. PEM Report Number 4. Ciprofloxacin. Pharmacoepidemiol Drug Saf 1993 Jul–Oct; 2: 341–64
Reiter C, Pfeiffer M, Hullman RN. Brief report: safety of ciprofloxacin based on phase IV studies (“Anwendungsbeobachtung”) in the Federal Republic of Germany. Am J Med 1989 Nov 30; 87: 103S-6S
Jick SS, Jick H, Dean AD. A follow-up safety study of Ciprofloxacin users. Pharmacotherapy 1993 Sep–Oct; 13: 461–4
Ball P, Tillotson G. Tolerability of fluoroquinolone antibiotics. Past, present and future. Drug Saf 1995; 13: 343–58
Norrby SR, Lietman PS. Safety and tolerability of fluoroquinolones. Drugs 1993; 45 Suppl. 3: 59–64
Rahm V, Schacht P. Safety of Ciprofloxacin. A review. Scand J Infect Dis Suppl. 1989; 60: 120–8
Bianchi W, Maggiolo F, Ohnmeiss H. Ciprofloxacin in elderly patients with underlying chronic diseases. J Int Med Res 1988 Sep–Oct; 16: 386–93
Wolfson JS, Hooper DC. Overview of fluoroquinolone safety. Am J Med 1991 Dec 30; 91: 153S-61S
Arcieri GM, Becker N, Esposito B, et al. Safety of intravenous Ciprofloxacin. A review. Am J Med 1989 Nov 30; 87 Suppl. 5A: 92S–7S
Bassaris H, Akalin E, Calangu S, et al. A randomised, multinational study with sequential therapy comparing ciprofloxacin twice daily with ofloxacin once daily. Infection 1995; 23: 227–33
Winter S. Safety aspects of intravenous ciprofloxacin in general practice. Reactions Weekly 1995 Oct 14; 572: 3–4
Hayem G, Carbon C. A reappraisal of quinolone tolerability. The experience of their musculoskeletal effects. Drug Saf 1995; 13: 338–42
Phillips BM, David TJ. Pathogenesis and management of arthropathy in cystic fibrosis. J R Soc Med 1986; 79 Suppl. 2: 44–50
Pradhan KM, Arora NK, Jena A. Safety of ciprofloxacin therapy in children: magnetic resonance images, body fluid levels of fluoride and linear growth. Acta Paediatr 1995 May; 84: 555–60
Bethell DB, Hien TT, Phi LT, et al. Effects on growth of single short courses of fluoroquinolones. Arch Dis Child 1996; 74: 44–6
Polk RE. Drug-drug interactions with ciprofloxacin and other fluoroquinolones. Am J Med 1989 Nov 30; 87 Suppl. 5A: 76S–80S
Lomaestro BM, Baile GR. Absorption interactions with fluoroquinolones. 1995 update. Drug Saf 1995; 12: 314–33
Deppermann K-M, Lode H. Fluoroquinolones: interaction profile during enterai absorption. Drugs 1993; 45 Suppl. 3: 65–72
Batty KT, Davis TME, Ilett KF, et al. The effect of Ciprofloxacin on theophylline pharmacokinetics in healthy subjects. Br J Clin Pharmacol 1995 Mar; 39: 305–11
Davis RL, Quenzer RW, Kelly HW, et al. Effect of the addition of ciprofloxacin on theophylline pharmacokinetics in subjects inhibited by cimetidine. Ann Pharmacother 1992 Jan; 26: 11–3
Grasela JTH, Dreis MW. An evaluation of the quinolone-theophylline interaction using the Food and Drug Administration spontaneous reporting system. Arch Intern Med 1992 Mar; 152: 617–21
Loi C-M, Parker BM, Cusack BJ, et al. Individual and combined effects of cimetidine and ciprofloxacin on theophylline metabolism in male nonsmokers. Br J Clin Pharmacol 1993 Sep; 36: 195–200
Robson RA, Begg EJ, Atkinson HC, et al. Comparative effects of Ciprofloxacin and lomefloxacin on the oxidative metabolism of theophylline. Br J Clin Pharmacol 1990 Apr; 29: 491–3
Prince RA, Casabar E, Adair CG, et al. Effect of quinolone antimicrobials on theophylline pharmacokinetics. J Clin Pharmacol 1989 Jul; 29: 650–4
Polk RE, Gillum JG, Israel DS, et al. Effect of ciprofloxacin and clarithromycin on the metabolism of theophylline in healthy volunteers [abstract]. In: 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. 1993: 228
Vestal RE, Cusack BJ, Crowley JJ, et al. Aging and the response to inhibition and induction of theophylline metabolism. Exp Gerontol 1993 Jul–Oct; 28: 421–33
Batty KT, Davis TME, Ilett KF, et al. Effect of Ciprofloxacin on theophylline pharmacokinetics in healthy volunteers [abstract]. Aust J Hosp Pharm 1994 Feb; 24: 99
Davis JD, Brennan B, Aarons L, et al. Steady state effects of ciprofloxacin and enoxacin on theophylline pharmacokinetics [abstract]. Br J Clin Pharmacol 1992 Aug; 34: 169P
Davis JD, Aarons L, Houston JB. Relationship between enoxacin and ciprofloxacin plasma concentrations and theophylline disposition. Pharm Res 1994 Oct; 11: 1424–8
Mahr G, Sörgel F, Granneman GR, et al. Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine. Clin Pharmacokinet 1992; 22 Suppl. 1: 90–7
Parker AC, Preston T, Heaf D, et al. Inhibition of caffeine metabolism by ciprofloxacin in children with cystic fibrosis as measured by the caffeine breath test. Br J Clin Pharmacol 1994 Dec; 38: 573–6
Harder S, Fuhr U, Staib H. Ciprofloxacin-caffeine: a drug interaction established using in vivo and in vitro investigations. Am J Med 1989 Nov 30; 87 Suppl. 5A: 89–91
Nicolau DP, Nightingale CH, Tessier PR, et al. The effect of fleroxacin and ciprofloxacin on the pharmacokinetics of multiple-dose caffeine [abstract]. In: 5th International Symposium on New Quinolones. 1994: 71
Healy DP, Polk RE, Kanawati L, et al. Interaction between oral ciprofloxacin and caffeine in normal volunteers. Antimicrob Agents Chemother 1989 Apr; 33: 474–8
Brouwers JRBJ, Van der Kam HJ, Sijtsma J, et al. Important reduction of ciprofloxacin absorption by sucralfate and magnesium citrate solution. Drug Invest 1990; 2 (3): 197–9
Frost RW, Lasseter KC, Noe AJ. Effects of aluminium hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother 1992 Apr; 36: 830–2
Li RC, Nix DE, Schentag JJ. Interaction between ciprofloxacin and metal cations: its influence on physicochemical characteristics and antibacterial activity. Pharm Res 1994 Jun; 11: 917–20
Nix DE, Watson WA, Lener ME, et al. Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clin Pharmacol Ther 1989 Dec; 46: 700–5
Sanchez BM, Cabarga MM, Navarro AS, et al. A physico-chemical study of the interaction of ciprofloxacin and ofloxacin with polyvalent cations. Int J Pharm 1994 Jun 6; 106: 229–35
Lecomte S, Coupry C, Chenon MT, et al. Affinity of Sparfloxacin and 4 other fluoroquinolones for magnesium and effect on antibacterial activity [abstract]. Drugs 1993; 45 Suppl. 3: 148–9
Roush MK, Dupuis RE. Significance of the ciprofloxacin-antacid interaction. DICP 1991 May; 25: 473–5
Bayer Inc. Pharmaceutical Division. ciprofloxacin prescribing information. New Haven, Connecticut, USA, 1995.
Garrelts JC, Godley PJ, Peterie JD, et al. Sucralfate significantly reduces ciprofloxacin concentrations in serum. Antimicrob Agents Chemother 1990 May; 34: 931–3
Nix DE, Watson WA, Handy L, et al. The effect of sucralfate pretreatment on the pharmacokinetics of ciprofloxacin. Pharmacotherapy 1989; 9 (6): 377–80
Van Slooten AD, Nix DE, Wilton JH, et al. Combined use of ciprofloxacin and sucralfate. DICP 1991 Jun; 25: 578–82
Van Slooten AD, Nix DE, Wilton JH, et al. Combined use of ciprofloxacin and sucralfate. DICP 1991 Jun; 25: 578–82
Lubowski TJ, Nightingale CH, Sweeney K, et al. Effect of sucralfate on pharmacokinetics of fleroxacin in healthy volunteers. Antimicrob Agents Chemother 1992 Dec; 36: 2758–60
Sahai J, Healy DP, Stotka J, et al. The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin. Br J Clin Pharmacol 1993 Mar; 35: 302–4
Lomaestro BM, Bailie GR. Effect of staggered dose of calcium on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother 1991 May; 35: 1004–7
Lomaestro BM, Bailie GR. Effect of multiple staggered doses of calcium on the bioavailability of ciprofloxacin. Ann Pharmacother 1993 Nov; 27: 1325–8
Neuvonen PJ, Kivistö KT, Lehto P. Interference of dairy products with the absorption of ciprofloxacin. Clin Pharmacol Ther 1991 Nov; 50: 498–502
Frost RW, Carlson JD, Dietz AJ, et al. Ciprofloxacin pharmacokinetics after a standard or high-fat/high-calcium breakfast. J Clin Pharmacol 1989 Oct; 29: 953–5
Bertino Jr JS, Nafziger AN, Wong M, et al. Effect of a fat- and calcium-rich breakfast on pharmacokinetics of fleroxacin administered in single and multiple doses. Antimicrob Agents Chemother 1994 Mar; 38: 499–503
Polk RE, Healy DP, Sahai J, et al. Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother 1989 Nov; 33: 1841–4
Kara M, Hasinoff BB, McKay DW, et al. Clinical and chemical interactions between iron preparations and ciprofloxacin. Br J Clin Pharmacol 1991 Mar; 31: 257–61
Lehto P, Kivistö KT, Neuvonen PJ. The effect of ferrous sulphate on the absorption of norfloxacin, ciprofloxacin and ofloxacin. Br J Clin Pharmacol 1994 Jan; 37: 82–5
Campbell NRC, Hasinoff BB. Iron supplements: a common cause of drug interactions. Br J Clin Pharmacol 1991 Mar; 31: 251–5
Kara M, Hasinoff BB, McKay DW, et al. Clinical and chemical interactions between iron preparations and ciprofloxacin. Br J Clin Pharmacol 1991 Mar; 31: 257–61
Brouwers JRBJ, van der Kam HJ, Sijtsma J, et al. Decreased Ciprofloxacin absorption with concomitant administration of ferrous fumarate. Pharm Weekbl Sci 1990 Oct 19; 12: 182–3
Le PMP, Kitzis MD, Terdjman M, et al. Possible interaction of Ciprofloxacin with ferrous sulphate. J Antimicrob Chemother 1990 Jan; 25: 184–5
Piccolo ML, Toossi Z, Goldman M. Effect of coadministration of a nutritional supplement on ciprofloxacin absorption. Am J Hosp Pharm 1994 Nov 1; 51: 2697–9
Mueller BA, Brierton DG, Abel SR, et al. Effect of enterai feeding with Ensure on oral bioavailabilities of ofloxacin and ciprofloxacin. Antimicrob Agents Chemother 1994 Sep; 38: 2101–5
Healy DP, Brodbeck M, Clendening C. Ciprofloxacin absorption impaired by enterai feedings given orally and via G-tube in patients [abstract]. In: 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1994: 18
Healy DP, Brodbeck M, Clendening C. Ciprofloxacin absorption is imparied in patients by enterai feedings given orally and via G-tube and J-tube [abstract]. Pharmacotherapy 1995 Jan-Feb; 15: 112
Yuk JH, Nightingale CH, Sweeney KR, et al. Relative bioavailability in healthy volunteers of ciprofloxacin administered through a nasogastric tube with and without enterai feeding. Antimicrob Agents Chemother 1989 Jul; 33: 1118–20
Yuk JH, Nightingale CH, Quintiliani R, et al. Absorption of ciprofloxacin administered through a nasogastric or a nasoduodenal tube in volunteers and patients receiving enteral nutrition. Diagn Microbiol Infect Dis 1990 Mar–Apr; 13: 99–102
Noer BL, Angaran DM. The effect of enterai feedings on ciprofloxacin pharmacokinetics [abstract]. Pharmacotherapy 1990; 10 (3): 254
Healy DP, Brodbeck MC, Clendening CE. Ciprofloxacin absorption is impaired in patients given enterai feedings orally and via gastrostomy and jejunostomy tubes. Antimicrob Agents Chemother 1996; 40: 6–10
Sahai J, Gallicano K, Oliveras L, et al. Cations in the didanosine tablet reduce ciprofloxacin bioavailability. Clin Pharmacol Ther 1993 Mar; 53: 292–7
Gallicano K, Sahai J, Khaliq S, et al. Effects of the antacids in didanosine tablet formulations on the absorption of ciprofloxacin [abstract]. Pharm Res 1992 Oct; 9 Suppl.: 328
Bianco TM, Bussey HI, Farnett LE, et al. Potential warfarin-ciprofloxacin interaction in patients receiving long-term anticoagulation. Pharmacotherapy 1992; 12 (6): 435–9
Mott FF, Murphy S, Hunt V. Ciprofloxacin and warfarin. Ann Intern Med 1989 Sep 15; 111: 542–3
Kamada AK. Possible interaction between ciprofloxacin and warfarin. DICP 1990 Jan; 24: 27–8
Jolson HM, Tanner LA, Green L. Adverse reaction reporting of interaction between warfarin and fluoroquinolones. Arch Intern Med 1991 May; 151: 1003–4
Rindone JP, Keuey CL, Jones WN, et al. Hypoprothrombinemic effect of warfarin not influenced by ciprofloxacin. Clin Pharm 1991 Feb; 10: 136–8
Israel DS, Stotka J, Rock W, et al. Effect of ciproflox on the pharmacokinetics and pharmacodynamics of warfarin. Clin Infect Dis 1996; 22: 251–6
Dillard ML, Fink RM, Parkerson R. Ciprofloxacin-phenytoin interaction [letter]. Ann Pharmacother 1992 Feb; 26: 263
Job ML, Arn SK, Strom JG, et al. Effect of ciprofloxacin on the pharmacokinetics of multiple-dose phenytoin serum concentrations. Ther Drug Monit 1994 Aug; 16: 427–31
Schroeder D, Frye J, Alldredge B, et al. Effect of Ciprofloxacin on serum phenytoin concentrations in epileptic patients [abstract]. Pharmacotherapy 1991; 11 (3): 275
Hull RL, Bartel L. Possible phenytoin-ciprofloxacin interaction [letter]. Ann Pharmacother 1993 Oct; 27: 1283
Hoey LL, Lake KD. Does ciprofloxacin interact with cyclosporine?. Ann Pharmacother 1994 Jan; 28: 93–6
Nasir M, Rotellar C, Hand M, et al. Interaction between ciclosporin and ciprofloxacin. Nephron 1991 Feb; 57: 245–6
Lang J, Finaz DVJ, Garraffo R, et al. Cyclosporine (cyclosporin A) pharmacokinetics in renal transplant patients receiving ciprofloxacin. Am J Med 1989 Nov 30; 87 Suppl. 5A: 82–5
Avent CK, Krinsky D, Kirklin JK, et al. Synergistic nephrotoxicity due to ciprofloxacin and cyclosporine. Am J Med 1988 Sep; 85: 452–3
Eiston RA, Taylor J. Possible interaction of ciprofloxacin with cyclosporin A [letter]. J Antimicrob Chemother 1988 May; 21: 679–80
Tan KK, Trail AK, Shawket S. Co-administration of ciprofloxacin and cyclosporin: lack of evidence for a pharmacokinetic interaction. Br J Clin Pharmacol 1989 Aug; 28: 185–7
Robinson JA, Venezio FR, Costanzo-Nordin MR, et al. Patients receiving quinolones and cyclosporine after heart transplantation. J Heart Transplant 1990 Jan–Feb; 9: 30–1
Ball AP. Ciprofloxacin: an overview of adverse experiences. J Antimicrob Chemother 1986; 18 Suppl. D: 187–93
Lomaestro BM, Lesar TS. Continuing problem of ciprofloxacin administered with interacting drugs. Am J Hosp Pharm 1994 Mar 15; 51: 832
Echols RM. The selection of appropriate dosages for intravenous ciprofloxacin. J Antimicrob Chemother 1993 May; 31: 783–7
Bauernfeind A. Questioning dosing regimens of ciprofloxacin. J Antimicrob Chemother 1993 May; 31: 789–98
Schaad UB. Use of the new quinolones in pediatrics. Isr J Med Sci 1994 May–Jun; 30: 463–8
Eliopoulos GM. In vitro activity of fluoroquinolones against Gram-positive bacteria. Drugs 1995; 49 Suppl. 2: 48–57
Author information
Authors and Affiliations
Additional information
Various sections of the manuscript reviewed by: P. Ball, Infectious Diseases Unit, Victoria Hospital, Fife, Scotland; M. Cruciani, Istituto di Immunologia e Malattie Infettive, Universita di Verone, Verona, Italy; J. Garau, Department of Medicine, Hospital de Mútua de Terrassa, Barcelona, Spain; F.W. Goldstein, Laboratoire de Microbiologie Médicale, Fondation Hôpital Saint-Joseph, Paris, France; E. Gotuzzo, Institute de Medicina Tropical ‘Alexander von Humboldt’, Universidad Peruana Cayetano Heredia, Lima, Peru; D.R.P. Guay, Section of Clinical Pharmacy, St Paul-Ramsey Medical Center, St Paul, Minnesota, USA; N. Høiby, Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark; M. Malena, Istituto di Immunologia e Malattie Infettive, Universita di Verone, Verona, Italy; J. O’Neil, Department of Pharmacy, Brockton Hospital, Brockton, Massachusetts, USA; R. Raz, Infectious Disease Unit, Central Emek Hospital, Afula, Israel; U.B. Schaad, Department of Pediatrics, University of Basel, Basel, Switzerland; J.P. Thys, Infectious Disease Clinic, Erasme University Hospital, Brussels, Belgium; R. Wise, Department of Medical Microbiology, Dudley Road Hospital, Birmingham, England.
Rights and permissions
About this article
Cite this article
Davis, R., Markham, A. & Balfour, J.A. Ciprofloxacin. Drugs 51, 1019–1074 (1996). https://doi.org/10.2165/00003495-199651060-00010
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199651060-00010